Mutationally-activated PI3’-kinase-α promotes de-differentiation of lung tumors initiated by the BRAF<sup>V600E</sup> oncoprotein kinase

J Edward van Veen<sup>1,2,3,4+</sup>, Michael Scherzer<sup>1,2</sup>, Julia Boshuizen<sup>3,4‡</sup>, Mollee Chu<sup>3,4§</sup>, Annie Liu<sup>1,2</sup>, Allison Landman<sup>1,4#</sup>, Shon Green<sup>3,4¶</sup>, Christy Trejo<sup>3,4**</sup>, Martin McMahon<sup>1,2,3,4*</sup>

<sup>1</sup>Huntsman Cancer Institute, University of Utah, Salt Lake City, United States; 2Department of Dermatology, University of Utah, Salt Lake City, United States; 3Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, United States; 4Department of Cellular & Molecular Pharmacology, University of California, San Francisco, San Francisco, United States

Abstract

Human lung adenocarcinoma exhibits a propensity for de-differentiation, complicating diagnosis and treatment, and predicting poorer patient survival. In genetically engineered mouse models of lung cancer, expression of the BRAF<sup>V600E</sup> oncoprotein kinase initiates the growth of benign tumors retaining characteristics of their cell of origin, AT2 pneumocytes. Cooperating alterations that activate PI3’-lipid signaling promote progression of BRAF<sup>V600E</sup>-driven benign tumors to malignant adenocarcinoma. However, the mechanism(s) by which this cooperation occurs remains unclear. To address this, we generated mice carrying a conditional <i>Braf<sup>CAT</sup></i> allele in which CRE-mediated recombination leads to co-expression of BRAF<sup>V600E</sup> and tdTomato. We demonstrate that co-expression of BRAF<sup>V600E</sup> and PIK3CA<sup>H1047R</sup> in AT2 pneumocytes leads to rapid cell de-differentiation, without decreased expression of the transcription factors NKX2-1, FOXA1, or FOXA2. Instead, we propose a novel role for PGC1α in maintaining AT2 pneumocyte identity. These findings provide insight into how these pathways may cooperate in the pathogenesis of human lung adenocarcinoma.

DOI: https://doi.org/10.7554/eLife.43668.001

Introduction

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death, with lung adenocarcinoma (LUAD) being the most common NSCLC subtype ([Siegel et al., 2016](https://doi.org/10.7554/eLife.43668)). Due to the morbidity and mortality associated with LUAD, there is an urgent need to better characterize how key genetic drivers contribute to the pathogenesis of this disease. To that end, since the original discovery of KRAS mutations in human lung cancer cells ([Capon et al., 1983](https://doi.org/10.7554/eLife.43668)), it has emerged that ~75% of LUADs display mutational activation of key components of receptor tyrosine kinase (RTK) signaling that, in turn, promote activation of RAS and its key downstream effectors: the RAF→MEK→ERK→MAP kinase (MAPK) and the PI3’-lipid pathways ([Cancer Genome Atlas Research Network, 2014](https://doi.org/10.7554/eLife.43668); [Heist and Engelman, 2012](https://doi.org/10.7554/eLife.43668)). Moreover, mutational activation of RTKs or downstream signaling proteins (e.g. EGFR/ERBB1, ALK, ROS1, NTRK, BRAF) serve as predictive biomarkers for the clinical deployment of FDA-approved inhibitors of these oncoprotein kinases for the treatment of genetically-defined subsets of lung cancer ([Drilon et al., 2018](https://doi.org/10.7554/eLife.43668); [Hyman et al., 2015](https://doi.org/10.7554/eLife.43668); [Rosell et al., 2012](https://doi.org/10.7554/eLife.43668); [Scagliotti et al., 2010](https://doi.org/10.7554/eLife.43668); [Shaw et al., 2013](https://doi.org/10.7554/eLife.43668); [Shaw et al., 2014](https://doi.org/10.7554/eLife.43668)).
Mutational activation of BRAF occurs in ~8% of LUAD, with the most common single mutation (BRAF<T1799A> encoding the BRAF<sup>V600E</sup> oncoprotein kinase (Cancer Genome Atlas Research Network, 2014). To model BRAF<sup>V600E</sup> driven cancers, we previously described Bra<sup>CA</sup> mice carrying a CRE-activated allele of Braf that expresses normal BRAF prior to CRE-mediated recombination, after which BRAF<sup>V600E</sup> (orthologous to human BRAF<sup>V600E</sup> and for simplicity henceforth referred to as BRAF<sup>V600E</sup>), is expressed from the endogenous chromosomal locus (Dankort et al., 2007). This mouse has proven useful in modeling many cancer types in which BRAF<sup>V600E</sup> is implicated as a driver oncoprotein (Charles et al., 2011; Dankort et al., 2009; Sakamoto et al., 2017; Trejo et al., 2013; Wang et al., 2012). Taken together, these studies indicate that BRAF mutation serves as a foundational initiating event for tumorigenesis in many target tissues. However, the progression of benign tumors initiated by BRAF<sup>V600E</sup> expression into malignant cancer invariably requires additional events such as silencing of tumor suppressors (e.g. INK4A-ARF, TP53, PTEN, CDX2) or activation of cooperating oncogenes (PIK3CA, CTNNB1, c-MYC) (Charles et al., 2014; Dankort et al., 2007; Dankort et al., 2009; Huillard et al., 2012; Juan et al., 2014; Sakamoto et al., 2017; Trejo et al., 2013; Tsao et al., 2004; Yu et al., 2009).

In mouse models of lung carcinogenesis, there are key similarities between the early stages of tumorigenesis observed in response to expression of either the KRAS<sup>G12D</sup> or BRAF<sup>V600E</sup> oncoproteins (Dankort et al., 2007; Trejo et al., 2012). While tumors initiated by BRAF<sup>V600E</sup> remain as benign adenomas with certain features of senescence (Dankort et al., 2007; Jackson et al., 2001), a proportion of KRAS<sup>G12D</sup> initiated lung tumors progress to frank adenocarcinomas within six months, most likely due to the ability of KRAS<sup>G12D</sup> to activate the PI3'-kinase signaling pathway (Castellano et al., 2013; Murillo et al., 2018; Rodriguez-Viciana et al., 1994; Vivanco and Sawyers, 2002; Yuan and Cantley, 2008). Consistent with this hypothesis, co-expression of BRAF<sup>V600E</sup>...
and PIK3CA<sup>H1047R</sup>, a mutationally-activated form of PI3'-kinase-α (PI3Kα), in AT2 pneumocytes leads to rapid growth of lung tumors, many of which display progression to frank malignancy bearing various hallmarks of the cognate human disease (Kinross et al., 2012; Trejo et al., 2013). Thus, these genetically manipulated mice provide a unique opportunity to genetically and biochemically separate and analyze the effects of activation of these two critical downstream arms of RTK→RAS signaling individually or in combination.

Whereas the original Braf<sup>CA</sup> mouse allowed insights into cancer initiation, progression and therapy, there remain many questions that this mouse is inadequately configured to address. For example, it is not trivial to identify and isolate pure populations of tumor cells without significant stromal contamination, particularly in contexts when tumor cells are rare, such as in the earliest stages of tumorigenesis, or in the context of minimal residual disease following pathway-targeted inhibition of BRAF<sup>V600E</sup> signaling (Dankort et al., 2007). To address these issues we and others have used mice carrying CRE-activated alleles that express fluorescent proteins, such as the mT-mG allele in which the activity of CRE recombinase silences the expression of tdTomato and elicits expression of EGFP (Muzumdar et al., 2007). However, this approach is confounded by the observation that not all cells expressing the desired oncoprotein also express EGFP and vice versa.

In order to unequivocally identify BRAF<sup>V600E</sup> expressing cells we have generated Braf<sup>CAT</sup> mice carrying a new CRE-activated Braf allele. Like the original Braf<sup>CA</sup> allele, Braf<sup>CAT</sup> encodes normal BRAF prior to CRE-mediated recombination, after which the recombined allele expresses a bicistronic <sup>Braf<sub>T1910A</sub>-P2A-tdTomato</sup> mRNA encoding both BRAF<sup>V600E</sup> and the red fluorophore tdTomato. Moreover, here we report the use of Braf<sup>CAT</sup> mice to explore the cooperation of oncogenic BRAF<sup>V600E</sup> and PI3K<sup>CA</sup> in lung carcinogenesis in greater mechanistic detail. In brief, BRAF<sup>V600E</sup>-driven lung tumors maintain expression of markers of AT2 identity, including the known regulators of AT2 identity, NKX2-1, FOXA1, and FOXA2 (Bruno et al., 1995; Camolotto et al., 2018; DeFelice et al., 2003; Hamvas et al., 2013; Lazzaro et al., 1991; Minoo et al., 1995; Snyder et al., 2013; Stahlman et al., 1996; Winslow et al., 2011; Yuan et al., 2000). By contrast, co-expression of BRAF<sup>V600E</sup> and PI3K<sup>α<sub>H1047R</sub></sup> leads to development of lung tumors that show variable and widespread loss of expression of markers of AT2 pneumocyte terminal differentiation including the well-characterized surfactant proteins, SFTPA, SFTPB, and SFTPC. Notably reduced expression of AT2 markers begins early in tumor development and occurs despite sustained NKX2-1, FOXA1, and FOXA2 expression in tumor cells. Hence, these data shed light on the mechanisms by which pathways that cooperate in lung tumorigenesis also cooperate to influence the differentiation state of tumor cells. Indeed, these findings bear similarity to observations in human lung adenocarcinomas in which poorly differentiated and metastatic cancers often show loss of expression of functional markers of lung identity despite maintaining expression of NKX2-1 (Yatabe et al., 2002). Consequently, our results may shed light on our understanding of human lung cancer progression and how normal lung epithelial cells may lose their differentiation status following activation of cooperating oncogenic pathways.

**Results**

**Generation of Braf<sup>CAT</sup> mice**

To generate a reporter of BRAF<sup>V600E</sup> oncoprotein expression, we linked its expression to the expression of the red fluorophore, tdTomato. To accomplish this, we made use of the design of the original Braf<sup>CA</sup> allele, in which the modified exon 18 and the remainder of the Braf allele is not transcribed prior to the action of CRE recombinase (Dankort et al., 2007) due to the insertion of a triple polyadenylation/mRNA transcription termination signal from SV40 (Figure 1A) (Srinivas et al., 2001). Consequently, we designed a targeting vector containing the final coding exon (22) of mouse Braf in which the stop codon was removed, followed by sequences encoding: 1. an in-frame glycine-serine-glycine-P2A self-cleaving peptide; 2. sequences encoding a membrane-tethered tdTomato-CAAX protein and; 3. a PGK-PURO selectable marker flanked by Frt sites for subsequent removal by FLP recombinase. Following electroporation of this construct into 2H1 Braf<sup>CA</sup>/ES cells, from which the original Braf<sup>CA</sup> mice were generated, 288 puromycin resistant clones were selected and screened by PCR for homologous recombination of the construct into the distal end of the Braf<sup>CA</sup> allele (Dankort et al., 2007). However, because the targeted ES cells are heterozygous for both...
Figure 1. Engineering and validation of a novel genetically engineered mouse model of BRAFV600E driven cancer. (A) The BrafCAT mouse builds upon the utility of the BrafCA mouse by tying expression of the oncogenic form of BRAF to expression of the red fluorescent protein, tdTomato. (B) Targeted BrafCAT ES cells display membrane associated red fluorescence only after the addition of TAT-CRE. (C) Comparison of Ad-CMV-CRE initiated lung
The following figure supplement is available for figure 1:
DOI: https://doi.org/10.7554/eLife.43668.003

Figure supplement 1. Engineering and validation of a novel genetically engineered mouse model of BRAFV600E driven cancer.
DOI: https://doi.org/10.7554/eLife.43668.004

normal Bras and the genetically manipulated BraFC alleles, and because there was no way to direct homologous recombination of the targeting vector to the previously targeted BraFC allele, we expected to target both homologues. Because BRAF is expressed in ES cells, we reasoned that modification of the normal allele would lead to ES cells with constitutive tdTomato-CAAX expression. Indeed, ~50% of PCR positive ES cell clones displayed constitutive red-fluorescence and were used to generate BraFTOM mice, in which tdTomato serves as a marker for any cells expressing normal BRAF (van Veen et al., 2016). By contrast, homologous recombination of the targeting vector into the BraFC allele should give rise to ES cells that do not express tdTomato due to the strong transcriptional termination signal. However, upon the addition of a cell permeable TAT-CRE protein to these cells, they should initiate the expression of both BRAFV600E and tdTomato (Figure 1B). Hence, this in vitro strategy allowed us to both identify appropriately targeted BraFC/+ ES cells and also indicated the appropriate functioning of the BraFC allele in response to CRE-mediated recombination prior to the generation of mice.

BraFC mice were generated from an appropriately targeted ES cell clone (1E6). To compare and contrast lung tumorigenesis following CRE-mediated recombination of the BraFC versus the original BraFC allele, mice of the appropriate genotype were infected with 10^7 pfu of Ad-CMV-CRE and analyzed at 8 weeks post-initiation (p.i.). We observed similar lung tumor formation in BraFC versus BraFC mice (Figure 1C) with the only discernable difference being the red fluorescence of lung tumors arising in the BraFC mice (Figure 1C,D and Figure 1—figure supplement 1A). In embryonic fibroblasts (MEFs) derived from BraFC mice, tdTomato fluorescence was detected by flow cytometry within 24 hr after expression of CRE and plateaued by 96 hr (Figure 1—figure supplement 1B). Following CRE-mediated recombination of BraFC in both MEFs and mouse lung cells (Figure 2B), the total amount of fluorescence from the BraFC allele was modest, likely due to being driven by the endogenous Bra promoter. However, tdTomato expressing cells were readily differentiated from autofluorescence by using a channel with no fluorophore (FITC) as a marker of autofluorescence, as has been previously described (Dane et al., 2006). Together, these data indicate that the BraFC allele functions analogously to the BraFC allele for the development of benign lung tumors following CRE-mediated initiation of BRAFV600E expression, and that cells expressing the BRAFV600E-P2A-tdTomato mRNA are readily identified by flow cytometry within a short time frame.

**Messenger RNA expression profiles of BRAFV600E/Pi3KαH1047R-driven lung tumors display diminished expression of AT2 pneumocyte specific genes**

To address mechanism(s) of cooperation between BRAFV600E and PI3'-lipid signaling in lung cancer progression, lung tumorigenesis was initiated in BraFC or BraFC; Pik3caH1047R (Pik3ca^{HR} hereafter) mice (Figure 2A) and analyzed at 2, 6 or 12 weeks p.i. (Figure 2B, for detailed gating strategy see Figure 2—figure supplement 1A). Importantly, to initiate oncoprotein expression solely in AT2 pneumocytes, we utilized Ad5-Spc-CRE, which restricts expression of CRE recombinase to Sftpc expressing cells (Sutherland et al., 2014). tdTomato expressing tumor cells were detectable by flow cytometry in both BraFC and BraFC; Pik3ca^{HR} mice as early as two weeks p.i. (Figure 2B). To identify alterations in mRNA expression that might explain how Pi3KαH1047R promotes malignant transformation of lung tumors initiated by BRAFV600E, we performed RNA-Seq analysis of flow sorted tdTomato+ lung tumor cells driven either by BRAFV600E alone or the combination of BRAFV600E plus Pi3KαH1047R. To gain a broad view of pathways and processes differing in these two tumor genotypes, we used Gene Set Enrichment Analyses (GSEA) (Figure 2C) on, samples from all time points (for GSEA analyses separated by week see Figure 2—figure supplement 1B). Comparing 'hallmark'
Figure 2. Examining global gene expression changes caused by combination of PI3K and MAPK activation using RNA-SEQ. (A) Tumors were adenovirally induced in cohorts of $\text{Braf}^{\text{CAT}+/+}$ and $\text{Braf}^{\text{CAT}+/+};\text{Pik3ca}^{\text{LAT-H1047R}+/+}$ mice with AT2 specific CRE expression. Mice harvested at 2 or 6 weeks were induced with $10^7$ PFU of Ad5-SpC-CRE, whereas mice harvested at 12 weeks were induced with $10^6$ PFU of Ad5-SpC-CRE. (B) Tumor cells were harvested from each genotype at 2 weeks, 6 weeks, and 12 weeks post tumor induction via tissue dissociation and FACS. (C) GSEA analyses profiling

van Veen et al. eLife 2019;8:e43668. DOI: https://doi.org/10.7554/eLife.43668

Research article
Cancer Biology
cells sorted from \( \text{BRAF}^{\text{V600E}}/\text{PI3K}^{\text{H1047R}} \) driven tumor bearing mice compared to \( \text{BRAF}^{\text{V600E}} \) driven tumor bearing mice, showing all 'Hallmark' gene sets along with gene sets constructed from the most specific markers of the cell types of the distal lung epithelium. Black bars indicate adj\( P < 0.05 \), gray bars indicate Benjamini-Hochberg corrected enrichment statistic adj\( P \geq 0.05 \). Here all time points combined within genotype. (D) GSEA mountain plot showing broad activation of PI3K signaling in \( \text{BRAF}^{\text{V600E}}/\text{PI3K}^{\text{H1047R}} \) driven tumor bearing mice; adj\( P \) is Benjamini-Hochberg corrected enrichment statistic. (E) GSEA mountain plot showing broad activation of EMT in \( \text{BRAF}^{\text{V600E}}/\text{PI3K}^{\text{H1047R}} \) driven tumor bearing mice; adj\( P \) is Benjamini-Hochberg corrected enrichment statistic. (F) GSEA mountain plot showing widespread loss of AT2 identity in \( \text{BRAF}^{\text{V600E}}/\text{PI3K}^{\text{H1047R}} \) driven tumor bearing mice; adj\( P \) is Benjamini-Hochberg corrected enrichment statistic.

DOI: https://doi.org/10.7554/eLife.43668.005

The following source data, source code and figure supplements are available for figure 2:

Source code 1. R script to perform gene set enrichment analysis on Figure 2—source data 1–2, as well as plot these results.

DOI: https://doi.org/10.7554/eLife.43668.007

Source data 1. DEseq2 output of differentially expressed genes comparing \( \text{BRAF}^{\text{V600E}}/\text{PI3K}^{\text{H1047R}} \) and \( \text{BRAF}^{\text{V600E}} \) driven tumors – all weeks pooled.

DOI: https://doi.org/10.7554/eLife.43668.008

Source data 2. DEseq2 output of differentially expressed genes comparing \( \text{BRAF}^{\text{V600E}}/\text{PI3K}^{\text{H1047R}} \) and \( \text{BRAF}^{\text{V600E}} \) driven tumors – weeks separated.

DOI: https://doi.org/10.7554/eLife.43668.009

Figure supplement 1. Examining global gene expression changes caused by combination of PI3K and MAPK activation using RNA-SEQ.

DOI: https://doi.org/10.7554/eLife.43668.006

gene sets (Broad Institute MSigDB: Hallmarks), and consistent with the engineered characteristics of the lung tumor cells, GSEA revealed that PI3K→AKT→MTOR signaling (Figure 2C and D) and epithelial→mesenchymal transition (Figure 2C and E) related genes were significantly elevated in \( \text{BRAF}^{\text{V600E}}/\text{PI3K}^{\text{H1047R}} \)-driven lung tumors compared to \( \text{BRAF}^{\text{V600E}} \) driven tumors. To examine differentiation state we constructed gene sets comprised of the 100 most specific described mRNA markers of the different cell types expressed in the distal lung epithelium (Han et al., 2018; Treutlein et al., 2014) namely alveolar type 1 (AT1) and type 2 (AT2) pneumocytes, as well as club and ciliated cells, hereafter referred to as AT1-100, AT2-100, club-100, and ciliated-100, respectively. Despite these gene sets representing related cell types of the distal lung epithelium, there is only modest overlap between their members, ranging from 2 to 12 of the 100 genes. GSEA using these gene sets demonstrated that, compared to \( \text{BRAF}^{\text{V600E}} \) expressing tumor cells, \( \text{BRAF}^{\text{V600E}}/\text{PI3K}^{\text{H1047R}} \) expressing tumor cells showed a significant decrease (adj. \( p = 0.01 \)) in expression of transcripts associated with AT2 cell identity (Figure 2C and F). This effect encompassed nearly all AT2 markers including the classical markers, \( Sftpab/c \), and newly described markers detected in many different gene classes including \( Lcn2 \) (lipid transporter), \( Bex2 \) (transcription factor), and \( Dlk1 \) (encoding a non-canonical NOTCH ligand). Together these data suggest that \( \text{PI3K}^{\text{H1047R}} \) signaling promotes reduced expression of markers of AT2 differentiation. Notably, when examined in parallel with 50 hallmark gene sets and markers of other cell types in the distal lung epithelium, the loss of expression of AT2 mRNAs was the strongest effect observed in association with PI3K\( ^{\text{V600E}} \)/PI3K\( ^{\text{H1047R}} \)-driven tumors – weeks separated. (Figure 3B and Figure 2—figure supplement 1B) and 12 weeks (Figure 3C and Figure 2—figure supplement 1B) p.i. Hence the effects of PI3K\( ^{\text{H1047R}} \) on expression of AT2 differentiation markers initiates more rapidly than has been reported in tumors driven by KRAS\( ^{G12D} \) (Desai et al., 2014), KRAS\( ^{G12D}/\text{TP53}^{\text{Null}} \) (Winslow et al., 2011), KRAS\( ^{G12D}/\text{CTNNB1}^{\text{Δex3}} \) (Pacheco-Pino et al., 2011), BRAF\( ^{V600E}/\text{TP53}^{\text{Null}} \) (Garnett et al., 2017; Shai et al., 2015), or BRAF\( ^{V600E}/\text{CTNNB1}^{\text{Δex3}} \) (Juan et al., 2014). In addition to reduced AT2 mRNA marker expression, \( \text{PI3K}^{\text{H1047R}} \) expression elicited a marked increase in AT1 marker expression when comparing all time points (Figure 2C). By contrast to the changes observed in AT2 marker expression, this change was most significant at earlier time points and was no longer observed to be significant by 12 weeks p.i. (Figure 2—figure supplement 1B). Together, these results suggest a capability of PI3'-lipid signaling to influence AT2 pneumocyte identity.
Figure 3. BRAF<sup>V600E</sup>/PI3Kα<sup>H1047R</sup> Driven Tumors Display Widespread Heterogeneous Loss of AT2 Marker Expression, Whereas BRAF<sup>V600E</sup> Driven Tumors Maintain AT2 marker expression. (A) GSEA mountain plots comparing gene expression profiles of cells sorted from Braf<sup>CAT/+;</sup>Pik3ca<sup>LAT-H1047R/+</sup> mice to those from Braf<sup>CAT/+</sup> mice, using 100 specific markers of AT2 identity as the gene set. Analyses show comparison of tumors from the two genotypes at each time point analyzed, P value is enrichment statistic. (B) Tumors found in Braf<sup>CAT/+;</sup>Pik3ca<sup>LAT-H1047R/+</sup> mice have widespread variegated loss of expression of the functional AT2 marker, SFTPA, compared to tumors found in Braf<sup>CAT/+</sup> mice. Expression of CCA is seen in airways but not in tumors of either genotype. Dashed boxes highlight areas of increased magnification. Scale bars = 100 um. (C) CellProfiler based quantitation of SFTPA immunofluorescence. Wilcoxon rank sum p value = 0.00013 (D) Tumors found in Braf<sup>CAT/+;</sup>Pik3ca<sup>LAT-H1047R/+</sup> mice have widespread loss of expression of the functional AT2 marker, LYZ, compared to tumors found in Braf<sup>CAT/+</sup> mice. (E) CellProfiler based quantitation of LYZ immunofluorescence. Wilcoxon rank sum p value = 0.02224 (F) Tumors found in Braf<sup>CAT/+;</sup>Pik3ca<sup>LAT-H1047R/+</sup> mice have widespread loss of expression of the functional AT2 marker, SFTPC, compared to tumors found in Braf<sup>CAT/+</sup> mice. (G) CellProfiler based quantitation of SFTPC immunofluorescence. Wilcoxon rank sum p value = 0.02323.

DOI: https://doi.org/10.7554/eLife.43668.010

The following source data, source code and figure supplements are available for figure 3:

Source code 1. R script to perform gene set enrichment analyses on Figure 2—source data 2, as well as plot these results.
DOI: https://doi.org/10.7554/eLife.43668.012

Source code 2. R script to perform statistics on Figure 3—source data 1–3, as well as plot these results.
DOI: https://doi.org/10.7554/eLife.43668.013

Source code 3. Cellprofiler pipeline to quantify raw images, producing Figure 3—source data 1–3.
DOI: https://doi.org/10.7554/eLife.43668.014

Source data 1. Cellprofiler output quantifying SFTPA immunofluorescence in BRAF<sup>V600E</sup>/PI3Kα<sup>H1047R</sup> and BRAF<sup>V600E</sup> driven tumors.

Figure 3 continued on next page
**PI3Kα^{H1047R} cooperates with BRAF^{V600E} expression to promote loss of expression of lung tumor differentiation markers**

Consistent with the mRNA expression data, Ad5-Sftpc-CRE initiated BRAF^{V600E}/PI3Kα^{H1047R}-driven lung tumors displayed decreased expression of surfactant proteins A and C (SFTPA and SFTPC) and Lysozyme, all of which are AT2 pneumocyte markers (Figure 3B,D and F). We next built a pipeline in CellProfiler, which allows for quantification of immunofluorescence images with single cell resolution in thousands of cells algorithmically (Figure 3—figure supplement 1A–H). By this means we noted significant reductions of SFTPA, SFTPC, and LYZ expression at 12 weeks p.i. (Figure 3C, E and G. Wilcoxon p=0.0001, .02,. 02 respectively, data from Figure 3—source data 1, 2 and 3).

It has previously been suggested that a population of cells at the bronchioalveolar junction co-expressing SFTPC and club cell antigen (CCA) has properties of bronchio-alveolar stem cells (BASCs) (Kim et al., 2005), and also that ERK1/2 signaling tone allows for expansion of club cell derived tumors (Cicchini et al., 2017). Thus, a hypothesis that might explain our observations is that expression of PI3Kα^{H1047R} allows for enhanced expansion of BASC-derived tumors, which express lower levels of AT2 marker genes. We reject this hypothesis based on three lines of evidence. First, there did not appear to be two classes of BRAF^{V600E}/PI3KCA^{H1047R}-induced tumors with respect to AT2 marker expression. Instead, within each tumor we observed variegated loss of AT2 marker expression (Figure 3B,D,F insets). Second, to test whether CCA/SFTPC double positive cells might be the source of emergence of a separate tumor type, we co-stained our AT2 marker panel with antisera to detect expression of club cell antigen (CCA). While CCA staining was readily detectable in airways, it was not observed throughout the BRAF^{V600E}/PI3Kα^{H1047R}-driven tumors, including those cells that have reduced AT2 marker expression (Figure 3B,D and F). Finally, we observed tumors arising predominantly within alveolar spaces, a pattern characteristic of AT2-derived tumors, whereas club cell derived tumors tend to arise predominantly at bronchioalveolar duct junctions (Cicchini et al., 2017). Taken together, these data suggest that BRAF^{V600E}/PI3Kα^{H1047R}-driven lung tumors arise from AT2 cells but rapidly lose their differentiated identity under the influence of PI3'-lipid signaling.

**Cooperative signaling between PI3Kα^{H1047R} and BRAF^{V600E} promotes de-differentiation of AT2 cells despite expression of NKX2-1**

Extensive research demonstrates that the NKX2-1 and FOXA1/2 transcription factors pattern and maintain the differentiated identity of normal lung cells (Bruno et al., 1995; Camolotto et al., 2018; DeFelice et al., 2003; Hamvas et al., 2013; Lazzaro et al., 1991; Minoo et al., 1995; Snyder et al., 2013; Stahlman et al., 1996; Yuan et al., 2000). As these transcription factors also display decreased expression in some models of LUAD (Juan et al., 2014; Snyder et al., 2013; Winslow et al., 2011), we next examined if changes in bulk NKX2-1 or FOXA1/2 expression in BRAF^{V600E}/PI3KCA^{H1047R}-driven lung tumors might explain the observed alterations in AT2 marker gene expression. Analysis of RNA-Seq data showed no consistent decrease of NKX2-1 or FOXA1/2 mRNA expression in BRAF^{V600E}/PI3KCA^{H1047R}-driven lung tumors. As this was initially surprising, we sought to further verify that AT2 identity was lost independent of NKX2-1 expression levels or localization in BRAF^{V600E}/PI3KCA^{H1047R}-driven lung tumors. Dual color immunofluorescence staining demonstrated that the observed loss of AT2 identity is not associated with a decrease or change in nuclear localization of NKX2-1 at either 2 or 12 weeks p.i. (Figure 4A–B). Quantification of immunostaining supports this observation, with no significant alteration in nuclear NKX2-1 staining at 2 weeks, and only a slight but significant increase in nuclear NKX2-1 staining observed when comparing 12 week p.i. BRAF^{V600E}/PI3KCA^{H1047R}-driven tumors to paired BRAF^{V600E}-driven tumors.
Figure 4. Expression levels and localization of lung lineage survival transcription factors are maintained in BRAF\textsuperscript{V600E}/PI3K\textsubscript{a}H1047R driven tumors, including those cells which have lost expression of markers of AT2 identity. (A) BRAF\textsuperscript{V600E} driven hyperplasia and tumors display widespread expression of both SFTPA and nuclear localization of the lung lineage transcription factor, NKX2-1, at 2 and 12 weeks post initiation. Scale bar = 10 um. (B) BRAF\textsuperscript{V600E}/PI3K\textsubscript{a}H1047R driven hyperplasia and tumors show decreased SFTPA expression at 2 and 12 weeks post initiation. These tumors maintain NKX2-1 expression, indicating retention of lineage identity.

Figure 4 continued on next page
broad nuclear expression of NKX2-1, including those cells with decreased SFTPA expression (yellow arrowheads). (C) Quantitation showing no significant difference in NKX2-1 immunoreactivity at 2 weeks post initiation, but a slight increase in nuclear NKX2-1 at 12 weeks post initiation. Wilcoxon rank sum p values = 0.2, 0.02 respectively. (D) Significant reduction of SFTPA immunoreactivity seen in BRAFV600E/P13KαH1047R driven hyperplasia and tumors at both 2 and 12 weeks post initiation. Wilcoxon rank sum p values = 5e-5, 4e-5 respectively. (E) Cytoplasmic SFTPA immunoreactivity plotted versus nuclear NKX2-1 immunoreactivity in BRAFV600E driven hyperplasia and tumors at 2 and 12 weeks post initiation. Similar association seen at both time points (Rho = 0.23, .27 respectively). (F) Cytoplasmic SFTPA immunoreactivity plotted versus nuclear NKX2-1 immunoreactivity in BRAFV600E/P13KαH1047R driven hyperplasia and tumors at 2 and 12 weeks post initiation. Similar association seen at both time points (Rho = 0.23, .27 respectively). (G) Overlay of BRAFV600E/P13KαH1047R and BRAFV600E driven hyperplasia 2 weeks post initiation. Dashed line for each marker drawn at mean - one standard deviation of BRAFV600E driven tumors. BRAFV600E/P13KαH1047R tumors show fewer SFTPA+, NKX2-1 + cells, most strongly accounted for by an increase in SFTPA, NKX2-1 + cells. Chi square test associates genotype with distribution, p val <1e-5. (H) Overlay of BRAFV600E/P13KαH1047R and BRAFV600E driven tumors 12 weeks post initiation. Dashed line for each marker drawn at mean - one standard deviation of BRAFV600E driven tumors. BRAFV600E/P13KαH1047R driven tumors show fewer SFTPA+, NKX2-1 + cells, most strongly accounted for by an increase in SFTPA, NKX2-1 + cells. Chi square test associates genotype with distribution, p val <1e-5.

DOI: https://doi.org/10.7554/eLife.43668.018

The following source data, source code and figure supplements are available for figure 4:

Source code 1. R script to perform statistics on Figure 4—source data 1–2, as well as plot these results.
DOI: https://doi.org/10.7554/eLife.43668.020

Source code 2. Cellprofiler pipeline to quantify raw images from BRAFV600E/P13KαH1047R and BRAFV600E driven tumors, producing Figure 4—source data 1.
DOI: https://doi.org/10.7554/eLife.43668.021

Source code 3. Cellprofiler pipeline to quantify raw images from KRASG12D/P1K3CAH1047R and KRASG12D driven tumors, producing Figure 4—source data 2.
DOI: https://doi.org/10.7554/eLife.43668.022

Source data 1. Cellprofiler output quantifying immunofluorescence of SFTPA and NKX2-1 in BRAFV600E/P13KαH1047R and BRAFV600E driven tumors.
DOI: https://doi.org/10.7554/eLife.43668.023

Source data 2. Cellprofiler output quantifying immunofluorescence of SFTPA and NKX2-1 in KRASG12D/P1K3CAH1047R and KRASG12D driven tumors.
DOI: https://doi.org/10.7554/eLife.43668.024

Figure supplement 1. Expression levels and localization of lung lineage survival transcription factors are maintained in BRAFV600E/P13KαH1047R driven tumors. At both 2 and 12 weeks post initiation, producing Figure 4G–H. BRAFV600E/P13KαH1047R driven tumors show association of NKX2-1 and SFTPA stain-, NKX2-1 + cells, most strongly accounted for by an increase in SFTPA, NKX2-1 + cells. Chi square test associates genotype with distribution, p val <1e-5.

DOI: https://doi.org/10.7554/eLife.43668.019

(Figure 4C, data from Figure 4—source data 1). Quantification of the same tumors confirmed a significant decrease of SFTPA staining in BRAFV600E/P1K3CAH1047R-driven tumors first observed at 2 weeks and persisting at 12 weeks p.i. (Figure 4D). Since we performed our quantification with single cell resolution we were able to compare NKX2-1 and SFTPA immunofluorescence staining on a cell-by-cell basis (Figure 4E–H). BRAFV600E-driven tumors show association of NKX2-1 and SFTPA staining consistent across time points (Spearman Rho = 0.23-.27, Figure 4E). BRAFV600E/P1K3CAH1047R driven tumors by contrast initially show almost no association between levels of NKX2-1 and SFTPA (Spearman Rho = 0.07, Figure 4F), but by 12 weeks p.i. the association of these two markers has increased markedly (Spearman Rho = 0.40, Figure 4F). Because the reduction of SFTPA precedes the observed association of NKX2-1 and SFTPA, we conclude that other factors must explain the rapid reduction in SFTPA expression. Dividing tumor cells into classes representing NKX2-1 ± and SFTPA +/- (for definitions, see Materials and methods) shows significant effects (chi-squared p<0.001) of tumor genotype on co-expression of NKX2-1 and SFTPA (Figure 4G–H). At both 2 and 12 weeks p.i., the largest proportional increase driven by P1K3CAH1047R expression is seen in NKX2-1/SFTPA tumor cells (Figure 4G–H), implying that at both early and late time points, decreased expression of NKX2-1 cannot explain the observed decrease in SFTPA expression. Similarly, neither the expression of FOXA1 (Figure 4—figure supplement 1A) nor FOXA2 (Figure 4—figure supplement 1B) at 12 weeks p.i. correlated with decreased SFTPA expression as assessed by immunostaining. Nor is the phosphorylation status of NKX2-1 at a critical ERK targeted residue (pS327) associated with loss of SFTPA expression (Figure 4—figure supplement 1C). Together these data suggest that the decreased expression of markers of AT2 cell differentiation that we observed upon co-activation of PI3'-lipid signaling in BRAFV600E driven tumors is largely independent of the expression levels of these known regulators of AT2 cell identity. We also note that at later time points,
repression of NKX2-1, FOXA1, or FOXA2 protein expression in scattered cells may serve to augment the dedifferentiation phenotype that we observed beginning at 2 weeks p.i.

To test the generality of our results, we examined KRAS<sup>G12D</sup> (Figure 4—figure supplement 1D) and KRAS<sup>G12D/PIK3CA<sup>H1047R</sup></sup>-driven lung tumors (Figure 4—figure supplement 1E) at 16 weeks p.i., a time at which mutationally-activated PI3K<sup>α</sup>H1047R strongly enhances KRAS<sup>G12D</sup>-driven lung tumorogenesis (Green et al., 2015). Indeed, in this model, we observed a similar and significant decrease in SFTPA expression comparing KRAS<sup>G12D/PIK3CA<sup>H1047R</sup></sup>- to KRAS<sup>G12D</sup>-driven tumors (Figure 4—figure supplement 1D,E,G, data from Figure 4—source data 2), which did not correspond to reduced NKX2-1 expression (Figure 4—figure supplement 1E,F). Intriguingly, although mutationally-activated KRAS<sup>G12D</sup> is reported to activate PI3′-lipid signaling in lung tumors (Castellano et al., 2013; Engelman et al., 2008; Gupta et al., 2007b; Molina-Arcas et al., 2013; Murillo et al., 2018; Rodriguez-Viciana et al., 1994), we did not observe extensive loss of SFTPA immunoreactivity in these tumors (Figure 4—figure supplement 1D). Both KRAS<sup>G12D/PIK3CA<sup>H1047R</sup></sup>-driven tumors and KRAS<sup>G12D</sup>-driven tumors showed similarly modest association of SFTPA and NKX2-1 expression (Figure 4—figure supplement 1H–I). Taken together these data suggest that either there exist additional factors that regulate AT2 pneumocyte identity independently of the NKX2-1/FOXA1/FOXA2 regulatory axis, or that these well-known regulators of pneumocyte identity require the presence of one or more additional factor(s) for their transcriptional function.

To explore the increase in AT1 marker expression observed in BRAF<sub>V600E</sub>/PI3K<sub>α</sub>H1047R</sub>-driven tumors in more detail, we immunostained both early and late tumors for the expression of the AT1 marker AQP5. At 2 weeks p.i. we observed a striking increase in AQP5 expression when comparing BRAF<sub>V600E</sub>/PI3K<sub>α</sub>H1047R</sub>-driven tumors to BRAF<sub>V600E</sub>-driven tumors (Figure 5A and B, data from Figure 5—source data 1). Interestingly, at 12 weeks p.i. the difference in AQP5 immunoreactivity is no longer significant between BRAF<sub>V600E</sub>/PI3K<sub>α</sub>H1047R</sub> and BRAF<sub>V600E</sub>-driven tumors, mirroring our mRNA expression profiling results (Figure 2 and Figure 2—figure supplement 1b). The pattern of AQP5 expression likely explains this finding, as modest AQP5 staining is seen throughout BRAF<sub>V600E</sub>-driven tumors as previously reported (Trejo et al., 2013), whereas BRAF<sub>V600E</sub>/PI3K<sub>α</sub>H1047R</sub>-driven tumors show strong AQP5 in some areas and essentially absent AQP5 in other areas (Figure 5A). Co-immunostaining of AQP5 and LYZ showed similar patterns in which BRAF<sub>V600E</sub>-driven tumors display widespread expression of both of AT1 and AT2 markers (Figure 5C). By contrast, BRAF<sub>V600E</sub>/PI3K<sub>α</sub>H1047R</sub>-driven tumors show some areas that are double positive for both AQP5 and LYZ (Figure 5C, cyan arrowheads), some areas with only expression of AQP5 (Figure 5C, green arrowheads), some areas with only expression of LYZ (Figure 5C, red arrowheads), and some areas where neither is expressed (Figure 5C, yellow arrowheads). Quantification of these data shows correlation (Spearman Rho = 0.54) between AQP5 and LYZ in BRAF<sub>V600E</sub>-driven tumors (Figure 5D), but lower correlation (Spearman Rho = 0.13) between these markers in BRAF<sub>V600E</sub>/PI3K<sub>α</sub>H1047R</sub>-driven tumors (Figure 5E). Comparing these two tumor types directly shows a significant effect of genotype on staining distribution (Figure 5F), with BRAF<sub>V600E</sub>/PI3K<sub>α</sub>H1047R</sub>-driven tumors showing a strong decrease in AQP5/<sub>LYZ</sub> double positive cells, with corresponding increases in each of the remaining classes of cells (AQP5+/LYZ; AQP5/<sub>LYZ</sub>; and AQP5+/LYZ).

Co-expression of AT1 or AT2 markers in BRAF<sub>V600E</sub>-driven tumors is reminiscent of what is observed in bipotent progenitor cells, which are reported to give rise to both AT1 and AT2 cells (Desai et al., 2014). To search for additional indicators of a bipotent progenitor like state induced by BRAF<sub>V600E</sub>-MEK→ERK signaling, we analyzed transmission electron micrographs of BRAF<sub>V600E</sub>-driven lung tumor sections from suitably manipulated Braf<sup>+/−</sup> mice 11 weeks p.i. Normal AT2 cells display a cuboidal morphology and contain many surfactant rich lamellar bodies (Figure 5—figure supplement 1A, cyan). BRAF<sub>V600E</sub>-driven tumor cells displayed gross morphological similarities to AT2 cells (Figure 5—figure supplement 1B), but in a subset of tumor cells large vacuoles, not seen in normal AT2 cells, were observed (Figure 5—figure supplement 1B, purple). Enhanced magnification of these structures demonstrated a rough chrysanthemum like pattern of electron dense material (Figure 5—figure supplement 1C) characteristic of glycogen storage (Revel, 1960). As glycogen storage vacuoles are another hallmark of bipotent progenitor cells (Desai et al., 2014), we propose that BRAF<sub>V600E</sub>-MEK→ERK signaling alone drives AT2 pneumocytes toward this fate. As BRAF<sub>V600E</sub>/PI3K<sub>α</sub>H1047R</sub>-driven tumors show some cells with co-expression of AT1 and AT2 markers, and many cells with reductions of either or both of these marker classes, we believe the coincident
Figure 5. BRAF\(^{V600E}/\)PI3K\(^{a\,H1047R}\) and BRAF\(^{V600E}\) driven tumors both show effects on differentiation status, with BRAF\(^{V600E}/\)PI3K\(^{a\,H1047R}\) driven tumors displaying more profound effects on identity. (A) BRAF\(^{V600E}/\)PI3K\(^{a\,H1047R}\) and BRAF\(^{V600E}\) driven hyperplasia both show immunoreactivity of the AT1 marker, AQP5, 2 weeks post initiation with BRAF\(^{V600E}/\)PI3K\(^{a\,H1047R}\) driven hyperplasia showing enhanced immunostaining. BRAF\(^{V600E}/\)PI3K\(^{a\,H1047R}\) and BRAF\(^{V600E}\) driven tumors also show immunoreactivity of AQP5 12 weeks post initiation with BRAF\(^{V600E}/\)PI3K\(^{a\,H1047R}\) driven tumors showing a more...
variable pattern of immunostaining. Scale bars = 100 um. (B) Quantitation demonstrating significant effect of PI3KaH1047R on AQP5 immunoreactivity in BRAFV600E-driven tumors 2 weeks post initiation. No difference seen in AQP5 immunoreactivity between BRAFV600E/PI3KaH1047R and BRAFV600E-driven tumors 12 weeks post initiation. This appears to be the result of a slight increase in AQP5 immunoreactivity between 2 and 12 weeks in BRAFV600E-driven tumors and a more dramatic decrease in AQP5 immunoreactivity between 2 and 12 weeks in BRAFV600E/PI3KaH1047R-driven tumors. ANOVA p<1e-5, multiple comparisons done by Tukey’s Honest Significant Difference test, ****: p<1×10^-5. (C) BRAFV600E-driven tumors display widespread immunoreactivity to both AQP5 and the AT2 marker, LYZ, 12 weeks post initiation. BRAFV600E/PI3KaH1047R-driven tumors show cells with widely varied expression of differentiation markers, including AQP5+, LYZ+ (Cyan arrows); AQP5-, LYZ+ (Red arrows); AQP5+, LYZ- (Green arrows); and AQP5-, LYZ- (Yellow arrows) cells. Scale bars = 100 um. (D) BRAFV600E-driven tumors show relatively high association between AQP5 and LYZ immunoreactivity (Rho = 0.54). (E) BRAFV600E/PI3KaH1047R-driven tumors show relatively low association between AQP5 and LYZ immunoreactivity (Rho = 0.13). (F) Overlay of BRAFV600E/PI3KaH1047R- and BRAFV600E-driven tumors 12 weeks post initiation. Dashed line for each marker drawn at mean - one standard deviation of BRAFV600E-driven tumors. BRAFV600E/PI3KaH1047R-driven tumors show fewer AQP5+, LYZ- cells, most strongly accounted for by an increase in AQP5+, LYZ- cells, but with increases also seen in AQP5+, LYZ+ and AQP5-, LYZ- cells. Chi square test associates genotype with distribution, p val <1×10^-5.

DOI: https://doi.org/10.7554/eLife.43668.025

The following source data, source code and figure supplements are available for figure 5:

Source code 1. R script to perform statistics on Figure 4—source data 1, as well as plot these results.

DOI: https://doi.org/10.7554/eLife.43668.027

Source code 2. Cellprofiler pipeline to quantify raw images from BRAFV600E/PI3KaH1047R and BRAFV600E-driven tumors, producing Figure 5—source data 1.

DOI: https://doi.org/10.7554/eLife.43668.028

Source data 1. Cellprofiler output quantifying AQP5 and LYZ immunofluorescence in BRAFV600E/PI3KaH1047R and BRAFV600E-driven tumors.

DOI: https://doi.org/10.7554/eLife.43668.029

Figure supplement 1. BRAFV600E-driven lung tumors show characteristics of bipotent progenitor cells.

DOI: https://doi.org/10.7554/eLife.43668.026

activation of ERK1/2 plus PI3'-lipid signaling promotes more profound de-differentiation of AT2 cells.

PGC1α expression correlates with AT2 marker expression

To identify novel candidate transcription factors that may participate in the establishment or maintenance of AT2 pneumocyte identity and function (Figure 6A), we took a three-step approach. First, we performed whole transcriptome correlation network analysis using Weighted Gene Correlation Network Analysis (WGCNA) (Langfelder and Horvath, 2008) to identify potentially relevant gene modules (Figure 6B). The majority of the AT2-100 and AT1-100 mRNAs fell into a single cluster (Cluster 2 – Dark blue Figure 6B,C). Next, to identify candidate regulators within cluster 2, we filtered the 2852 mRNAs in this cluster to select for those with demonstrated roles in transcriptional regulation. Finally, we filtered these selected transcription factors for differential expression in BRAFV600E-vs BRAFV600E/PI3KaH1047R-driven lung tumors using a promiscuous cutoff of adjP <0.2. The intersection of these three methods left a single candidate, the nuclear receptor co-activator, PGC1α (Figure 6D). PGC1α is a known transcriptional regulator, clusters with the majority of AT1 and AT2 genes, and its mRNA is significantly decreased in BRAFV600E/PI3KaH1047R-driven tumors compared to BRAFV600E-driven tumors (Figure 6E). The control of PPARGC1A levels by PI3'-lipid signaling may also be true in human lungs: those bearing mutations in either PIK3CA, AKT1, or PTEN have significantly reduced PPARGC1A mRNA expression compared to tumors bearing none of these mutations (Figure 6—figure supplement 1A). Finally, we sought to determine if PGC1α expression correlates with maintenance of lung identity on a cell-by-cell basis within BRAFV600E/PI3KaH1047R-driven tumors in mice. Immunostaining revealed that cells with decreased expression of SFTA lack nuclear PGC1α (Figure 6F, red arrows). Conversely, tumor cells with detectable nuclear localization of PGC1α display readily detectable levels of SFTA (Figure 6F, green arrows).

Silencing of PGC1α expression promotes de-differentiation of BRAFV600E-driven lung tumors

To directly test if PGC1α regulates AT2 identity, we crossed a floxed, conditional null allele of Pgc1α (Ppargc1alox/lox) to BrafcAT mice and generated littermate cohorts of BrafcAT, Ppargc1alox/lox, and
**Figure 6.** Loss of PGC1α Expression Correlates With Change in Expression of Lung Markers. (A) Hypothetical model showing an additional factor cooperating with lung lineage transcription factors that is downregulated upon dual arm mutational activation of growth factor signaling. (B) Weighted gene correlation network analysis (WGCNA) heat map identifies 21 correlated gene expression modules. Gene tree shows relationship of individual genes, where multi-color bars adjacent to heat map identify individual clusters. (C) Table summarizing result of WGCNA analysis and AT1/AT2 expression clustering heatmap. (D) Schematic showing relationship of PGC1α and transcription factors. (E) Table summarizing result of WGCNA analysis and AT1/AT2 expression clustering heatmap. (F) 12 Weeks Post Induction. *Braf^CAT/+*; *Pik3ca^LA-H1047R/+*.
memberships. Cluster number is listed adjacent to color corresponding to cluster in (B). For each cluster, shown is the total number of genes along with the number of AT1 and AT2 marker genes from AT1-100 and AT2-100. Cluster two contains the majority of both AT1 and AT2 marker genes. (D) A three factor approach to identify novel regulators of pneumocyte identity. Within the intersection of differentially expressed genes, genes co-regulated with the majority of AT1 and AT2 specific genes, and known transcription factors, lies a single gene, PGC1α. (E) PGC1α is significantly downregulated in BRAF<sup>V600E</sup>/PI3K<sup>Δ1047R</sup> driven tumors compared to BRAF<sup>V600E</sup> driven tumors; adjP is Benjamini-Hochberg corrected P value from DESeq2. (F) Decreased nuclear PGC1α immunoreactivity (red arrows) correlates with loss of AT2 identity on a cell by cell basis. AT2 identity is maintained in those cells which maintain nuclear PGC1α immunoreactivity (green arrows).

**Source code 1.** R script to perform weighted correlation network (WGCNA) on Figure 6—source data 1.

**Source data 1.** DEseq2 normalized RNA-seq count output of all BRAF<sup>V600E</sup>/PI3K<sup>Δ1047R</sup> and BRAF<sup>V600E</sup> driven tumors.

**Figure supplement 1.** Mutations predicted to affect the PI3' lipid signaling pathway correlate with decreased PPARGC1A in human lung adenocarcinoma.

**Figure supplement 1—source data 1.** Ppargc1a FPKM values from human tumors.

PGC1α cooperates with NKX2-1 and FOXA1 to transactivate AT2 promoters

We next sought to test if the role of PGC1α in AT2 pneumocyte identity maintenance could be through direct action on the promoters of AT2 pneumocyte specific genes. As PGC1α generally co-activates nuclear receptors such as PPARγ, we sought to discover its potential binding partner relevant to AT2 pneumocyte gene regulation. To this end we performed a motif discovery analysis using Multiple Em for Motif Elicitation (MEME) (Bailey and Elkan, 1994; Bailey et al., 2009) algorithm and scanning the promoter regions of the AT2-100. The most enriched novel motif (Figure 7—figure supplement 1B–C) bears significant similarity to the known binding motif of the nuclear receptor, NR5A2 (JASPAR: MA0505.1), also known as Liver Receptor Homolog (LRH) 1 (Gupta et al., 2007a).

To functionally test whether PGC1α can act at promoter sequences to regulate key markers of AT2 identity, we generated reporter constructs in which ~ 5 kb upstream of the transcription start site (TSS) of the genes encoding surfactant proteins A, B, or C (Sftpa/b/c) was inserted into a luciferase reporter plasmid. Transfection of individual expression constructs for NR5A2, PGC1α, NKX2-1, or FOXA1 showed modest promoter induction of up to four fold over mock-transfected cells (Figure 7D). However, co-transfection of these four factors together showed a dramatic 25–100 fold induction of the SFTPAs, SFTPB, and SFTPC promoters. Importantly, the absence of PGC1α severely hampered the ability of NKX2-1 and FOXA1 to transactivate the surfactant A and B promoters, suggesting a functional role of PGC1α in the transcriptional transactivation of AT2 promoters.
Figure 7. PGC1α is required for maintenance of lung identity in BRAF<sup>V600E</sup>-driven tumors. (A) Tumors were induced in cohorts of Bra<sup>CAT/+</sup> and Bra<sup>CAT/+</sup>;Ppargc1α<sup>−/−</sup> mice via intranasal instillation of 10<sup>6</sup> PFU Ad5-SpC-CRE and harvested from each genotype 12 weeks post tumor induction via tissue dissociation and FACS. GSEA analyses of hallmark pathways and lung identity gene sets. Black bars indicate adjP < .05, gray bars indicate Benjamini-Hochberg corrected enrichment statistic adjP ≥ .05. (B) Immunostaining confirms decreased expression of the AT2 markers SFTPA and LYZ.
Figure 7 continued

in BRAFV600E/PGC1αNULL tumors. (C) Quantitation demonstrating a significant decrease of LYZ immunoreactivity in BRAFV600E/PGC1αNULL tumors. Wilcoxon rank sum p val. = 0.0288. (D) Luciferase assays in HEK293T cells demonstrating the cooperation of NXX2-1, FOXA1, PGC1α, and NR5A2 in transactivation of surfactant promoters. All three promoters showed significant induction by ordinary one-way ANOVA (p<0.0001). Comparison of individual groups to mock transfected controls by Dunnett’s test for multiple comparisons: (*) p=0.0189, (****) p<0.0001. (E) Co-Immunoprecipitation of NXX2-1 by immunoprecipitation with a mouse monoclonal antibody recognizing PGC1α but not with IgG. (F) Co-Immunoprecipitation of PGC1α by immunoprecipitation with a mouse monoclonal antibody recognizing NXX2-1 but not with mouse IgG.

DOI: https://doi.org/10.7554/eLife.43668.035

The following source data, source code and figure supplements are available for figure 7:

Source code 1. R script to perform gene set enrichment analysis on Figure 7—source data 1, as well as plot these results.
DOI: https://doi.org/10.7554/eLife.43668.038

Source code 2. R script to perform statistics on Figure 7—source data 2, as well as plot these results eLife’s transparent reporting form.
DOI: https://doi.org/10.7554/eLife.43668.039

Source data 1. DEseq2 output of differentially expressed genes comparing BRAFV600E/PGC1αNULL and BRAFV600E/PGC1αHET driven tumors.
DOI: https://doi.org/10.7554/eLife.43668.040

Source data 2. Cellprofiler output quantifying immunofluorescence of LYZ in BRAFV600E/PGC1αNULL and BRAFV600E/PGC1αWT driven tumors.
DOI: https://doi.org/10.7554/eLife.43668.041

Source data 3. Data from luciferase assays looking for transactivation of Sftpa, Sftpβ, and Sftpc promoters.
DOI: https://doi.org/10.7554/eLife.43668.042

Figure supplement 1. PGC1α is required for maintenance of lung identity in BRAFV600E driven tumors.
DOI: https://doi.org/10.7554/eLife.43668.036

Figure supplement 2. Proposed mechanism of PI3'-kinase-α promoting de-differentiation of lung tumors initiated by the BRAFV600E oncoprotein kinase.
DOI: https://doi.org/10.7554/eLife.43668.037

PGC1α is found in complex with NXX2-1 in surfactant expressing cells

Based on the discovery that NR5A2 and PGC1α can cooperate with NXX2-1 and FOXA1 to transactivate AT2 pneumocyte promoters, we hypothesized that these proteins may exist in a biochemical complex. To test this directly, we used the immortalized mouse lung epithelial line MLE-12 (Wikenheiser et al., 1993). We first verified that these cells indeed express the pertinent proteins and maintain surfactant expression (Figure 7—figure supplement 1D). We next performed co-immunoprecipitation assays from MLE-12 cell extracts. While magnetic beads conjugated to mouse IgG did not enrich eluates for NXX2-1, magnetic beads conjugated to a mouse monoclonal antibody directed against PGC1α readily co-immunoprecipitated NXX2-1 (Figure 7E). To confirm this result, we showed that, while magnetic beads conjugated to rabbit IgG did not enrich eluates for PGC1α, magnetic beads conjugated to a rabbit monoclonal antibody directed against NXX2-1 also co-immunoprecipitated PGC1α (Figure 7F). Thus, PGC1α and NXX2-1 appear to co-exist in a complex in cells that express genes encoding AT2 expressed surfactant proteins.

Discussion

Genetically engineered mouse models have proven to be invaluable tools that complement the significant advances being made in the genetic and biochemical characterization of the initiation, progression and maintenance of human cancers. As genome sequencing efforts catalog clinically actionable mutations and their correlations with the cancer’s observed phenotypes, directly testing how these mutations affect disease initiation, progression, and response to novel therapeutics becomes a high priority. Here we describe a new GEM model that has allowed a deeper dissection of the stages of BRAFV600E-driven lung cancer, a disease that kills ~4000 patients per year in the U.S. A. (Siegel et al., 2016). To engineer this mouse we employed a strategy in which the previously targeted CRE-activated BrafCA allele was re-targeted to allow for the expression of both BRAFV600E and tdTomato from a single bicistronic mRNA following CRE-mediated recombination. Consequently, all BRAFV600E expressing cells are predicted to be red fluorescent by virtue of co-expression of tdTomato. This is an alternative approach to the more widely employed method of using a fluorophore expressed in trans from a different promoter (e.g. Rosa26) the expression of which is co-activated by CRE recombinase (Livet et al., 2007; Madisen et al., 2010; Muzumdar et al., 2007;
The approach described here has both advantages and disadvantages compared to the use of a fluorophore expressed in trans approach. The main disadvantage of our approach appears to be the modest fluorescence emission of tdTomato when expressed downstream of a P2A element from the mutationally activated Braf<sup>F1910A</sup> mRNA. Many LSL-XFP alleles have been designed for very high levels of expression by the incorporation of enhancers and strong promoters, whereas our model is driven by the endogenous Braf enhancer/promoter sequences. Hence, although the level of tdTomato fluorescence in lung tumors arising in Braf<sup>CAT</sup> mice is readily detected by flow cytometry, detection of tdTomato expression by immunohistochemistry in FFPE tissue sections is problematic. However, we have developed protocols that allow for detection of native tdTomato fluorescence in frozen sections (Figure 1D) or by a ligation proximity assay in FFPE sections (Daphne Pringle, unpublished). By contrast, the use of a fluorophore expressed in trans approach inherently relies on the simultaneous activity of CRE at distinct regions of the genome. Thus it is possible for the proto-oncogenic Braf<sup>CAT</sup> locus to be subject to CRE-mediated recombination without recombination of the reporter, or vice-versa. While this is acceptable for some applications, it adds confounding noise that may be amplified under conditions when tumor cells have been specifically depleted by the application of pathway targeted or immunomodulatory therapy that has negligible effect on normal cells. Our approach avoids this noise entirely and results in a level of fluorescence that is directly correlated with expression of BRAF<sup>V600E</sup> on a cell-by-cell basis (van Veen et al., 2016). Importantly, our approach is especially compatible with the emerging technology of single cell RNA sequencing (scRNA-Seq), in which it is desirable to isolate single BRAF<sup>V600E</sup> oncogene kinase expressing cells for analysis.

Our studies were aided greatly by recent characterizations of the gene expression changes accompanying development of the mouse distal lung epithelium (Treutlein et al., 2014) and KRAS<sup>G12D</sup>-mediated oncogenic transformation of AT2 cells (Desai et al., 2014). Using scRNA-Seq, the authors reconstructed the lineage hierarchies of AT1, AT2, club and ciliated cells, as well as provided a new list of markers useful in identifying these major cell types of the distal lung epithelium. We used these marker lists extensively and without bias or selection for most of our analyses. Importantly, we constructed gene sets for the GSEA analyses that showed widespread decreased AT2 marker expression in BRAF<sup>V600E</sup>/PI3CA<sup>H1047R</sup>-driven lung tumors. Analysis of the full complement of AT2 markers paints a dramatic picture; nearly every AT2 identity marker is diminished in expression in BRAF<sup>V600E</sup>/PI3CA<sup>H1047R</sup>-driven tumors as compared to BRAF<sup>V600E</sup>-driven tumors, as early as two weeks p.i. Importantly we noted a similar early and consistent repression of PGC1α expression in BRAF<sup>V600E</sup>/PI3CA<sup>H1047R</sup>-driven tumors. Here our data support previous findings that indicate that PGC1α expression is repressed by the PI3K–AKT signaling axis via three insulin response sequences found in the PGC1α promoter shown to bind to the AKT-regulated FOXO1 transcription factor (Daitoku et al., 2003; Kemper et al., 2014). It has also been suggested that BRAF<sup>V600E</sup> signaling can suppress PGC1α expression via the MITF transcription factor in melanoma, further demonstrating the complicated interplay between growth factor signaling and oxidative phosphorylation (Haq et al., 2013), though this study did not examine any potential connection of PGC1α to tumor cell differentiation status.

PI3CA mutation is found in ~4% of human LUAD (Campbell et al., 2016) that, although quite rare, still represents a significant patient population due to the high prevalence of lung cancer in our society. Previous studies have demonstrated that the ability of mutationally-activated KRAS<sup>G12D</sup> to bind and activate PI3Kα is critical for its tumor promoting activities, as well as tumor maintenance (Castellano et al., 2013; Gupta et al., 2007b; Molina-Arcas et al., 2013; Murillo et al., 2018). Despite this, activation of PI3′-lipid signaling remains rate limiting with respect to tumor initiation and growth in KRAS<sup>G12D</sup>-driven lung tumors as evidenced by the strong cooperation between KRAS<sup>G12D</sup> and PI3CA<sup>H1047R</sup> in promoting lung tumorigenesis in a GEM model (Green et al., 2015). This cooperation likely reflects the fact that the initial expression of KRAS<sup>G12D</sup> is a relatively weak activator of both PI3′-lipid signaling and the RAF→MEK→ERK pathways (Cicchini et al., 2017). Indeed, whereas KRAS<sup>G12D</sup> derived lung cancer cells show little phosphorylation of AKT at a key activating amino acid (S473), KRAS<sup>G12D</sup>/PI3CA<sup>H1047R</sup> derived cells show strong pS473-AKT phosphorylation (Green et al., 2015). Our results suggest that the lack of PI3′-lipid signaling in KRAS<sup>G12D</sup>-driven lung tumors is not only limiting in tumor growth, but in propensity for AT2 pneumocyte de-differentiation. Intriguingly, recent studies have shown that stromally derived IGF-1 promotes a cancer stem cell like phenotype in Kras mutated cell lines (Chen et al., 2014), via the...
PI3K→AKT signaling axis. It will be interesting to examine in future studies how various tumor genotypes and tumor microenvironments converge upon the initiation and evolution of LUAD dedifferentiation.

Lung adenocarcinoma differentiation status, as judged by pathological criteria, remains a critically important prognostic factor in predicting patient survival (Yoshizawa et al., 2011). However, only in recent years have we begun to understand the genetic aberrations that can directly promote loss of differentiation status. The protein most directly demonstrated to influence both lung adenocarcinoma differentiation status and progression is NKX2-1, a homeodomain transcription factor. Indeed, in the KrasLSL-G12D GEM model of KRASG12D-driven lung adenocarcinoma, NKX2-1 expression is diminished or silenced in the most poorly differentiated tumors. Moreover, shRNA-mediated inhibition of NKX2-1 expression is reported to enhance the metastatic potential of KRASG12D/TP53Null-driven lung cancer cells (Winslow et al., 2011). Interestingly, concomitant expression of KRASG12D with genetic silencing of NKX2-1 expression has qualitatively different effects, promoting trans-differentiation of tumor cells into a gastric fate resembling de-differentiated mucinous adenocarcinoma (Snyder et al., 2013), an effect that requires the activity of FOXA1/FOXA2 (Camolotto et al., 2018). Intriguingly, while even haploinsufficiency of NKX2-1 promoted the appearance of mucinous adenocarcinoma in the KrasLSL-G12D GEM model of lung adenocarcinoma, the same was not true in a lung adenocarcinoma model driven by expression of a mutationally-activated form of the EGF receptor (Maeda et al., 2012). In this model, haploinsufficiency of NKX2-1 slowed tumor progression rather than enhancing it. Importantly, loss-of-function mutations or silencing of NKX2-1 is a relatively infrequent event in lung adenocarcinoma. Instead NKX2-1 is often found as the most significantly focally amplified locus (Campbell et al., 2016). Further, in human NSCLC cell lines in which NKX2-1 is amplified, RNAi-mediated inhibition of NKX2-1 expression elicited decreased cell division and apoptosis (Kwei et al., 2008). Hence, the role of NKX2-1 in LUAD progression is thus simultaneously critically important and also complicated. In this case, GEM models provide an ideal system in which to study the contribution of individual mutations to each step of tumor initiation and progression without the complications of mutagen-induced genome hypermutation as is common in KRAS-mutated human lung cancer cells (Chalmers et al., 2017). While a wealth of literature has shown the direct effect of NKX2-1 on AT2 promoters (Bruno et al., 1995), and the importance of NKX2-1 in normal lung development (DeFelice et al., 2003), it has also been shown that transcriptional co-activators are critical for NKX2-1 function (Cassel et al., 2002; Di Palma et al., 2003; Park et al., 2004; Yi et al., 2002). Here we have shown that the binding motif of the nuclear receptor, NR5A2 is highly enriched in the promoters of AT2 specific genes. We also demonstrate that NR5A2, and its known co-factor PGC1α (Yazawa et al., 2010), can potently enhance the activity of NKX2-1 at the promoters for surfactant proteins A and B. Interestingly, while NR5A2 and PGC1α can activate the promoter of SFTPC alone, the added presence of NKX2-1 and FOXA1 does not further co-activate this promoter. It may be the case that PGC1α and NKX2-1 act independently at this promoter, or it may be that there are additional or alternative transcriptional regulators not present in 293 T cells which, when present, allow PGC1α and NKX2-1 to cooperate. In vivo, in BRAFV600E/PIK3CAH1047R-driven tumors, we observed an early decrease of PGC1α mRNA expression, and importantly, a correlation between decreased PGC1α and SFTPA on a cell-by-cell basis within tumors. Combined with functional data in GEM models in which PGC1α expression was genetically silenced, these data argue that mutational-activation of PI3'-lipid signaling in BRAFV600E-driven LUAD leads to diminished PGC1α expression, and that this reduced expression compromises the ability of NKX2-1/FOXA1 to maintain AT2 pneumocyte identity (Figure 7—figure supplement 2A). It is important to note that while genetic silencing of PGC1α recapitulated some aspects of PI3K activation in BRAFV600E-driven driven lung tumors, there were interesting differences, including an increase in markers of club and ciliated cell identity, and no significant effect on AT1 marker expression. It is therefore highly likely that amongst the pleiotropic effects of PI3'-lipid signaling, inhibition of PGC1α-mediated signaling represents one of many important effector pathways. This novel mechanism of lung identity regulation is made more important by the observation that it can be induced by mutational-activation of PI3Kα in both KRASG12D- and BRAFV600E-driven lung adenocarcinomas. Since the best characterized role of PGC1α is in the regulation of mitochondrial biogenesis, we were initially surprised to discover the cooperativity that PGC1α shows in the regulation of AT2 cell identity. However, it has recently emerged that crippling mitochondrial function via loss of the critical pyruvate transporter, MPC1, potently drives cells into a de-differentiated stem cell fate in drosophila and mouse intestinal cells.
cells (Schell et al., 2017). These studies, and the data presented here, suggest exciting future studies to examine the role of PGC1α to act as a pleiotropic effector of tumor cell growth and differentiation state downstream of PI3'-lipid signaling.

### Materials and methods

#### Key resources table

| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Gene (Mus musculus)               | Braf        |                     | Ensembl: ENSMUSG00000002413 |
| Gene (Mus musculus)               | Pik3ca      |                     | Ensembl: ENSMUSG00000027665 |
| Genetic reagent (Mus musculus)    | Braf<sup>CA</sup> | McMahon lab stock | MGI:Braf<sup>tm1Mmcm</sup> JAX:017837 RRID:IMSR_JAX:017837 |
| Genetic reagent (Mus musculus)    | Pik3ca<sup>H1047R</sup> | Wayne Phillips | MGI:Pik3ca<sup>tm1.1Waph</sup> RRID:MGI:5427584 |
| Genetic reagent (Mus musculus)    | Braf<sup>CAT</sup> | This paper          | N/A         | New genetically engineered mouse reported in this paper |
| Genetic reagent (Mus musculus)    | Kras<sup>LSL</sup> | The Jackson Lab     | MGI:Kras<sup>ls047</sup> JAX:008179 RRID:IMSR_JAX:008179 |
| Cell line (Mus musculus)          | MLE-12      | ATCC                | CRL-2110 RRID:CVCL_3751 |
| Cell line (Homo sapiens)          | 293T        | Lab Stock           | RRID:CVCL_0063 |
| Antibody                          | Mouse monoclonal PGC1α | Millipore | Cat# 1F3.9 RRID:AB_10806332 | Co-IP, 10 ug WB, 1:500 |
| Antibody                          | Rabbit polyclonal PGC1α | Millipore | Cat# AB3242 RRID:AB_2268462 | IHC, 1:50 WB, 1:500 |
| Antibody                          | Rabbit monoclonal NKX2-1 | Abcam | Cat# AB76013 RRID:AB_1310784 | Co-IP, 10 ug IHC, 1:250 WB, 1:1000 |
| Antibody                          | Rabbit polyclonal Phospho-S327-NKX2-1 | CST | Cat# 13608 RRID:AB_2798273 | IHC, 1:250 |
| Antibody                          | Rabbit monoclonal FOXA1 | Abcam | Cat# AB23738 RRID:AB_2104842 | IHC, 1:250 |
| Antibody                          | Rabbit monoclonal FOXA1 | CST | Cat# 58613 RRID:AB_2799548 | WB, 1:2500 |
| Antibody                          | Rabbit monoclonal FOXA2 | CST | Cat# D56D6 RRID:AB_10891055 | IHC, 1:250 WB, 1:1000 |
| Antibody                          | Rabbit monoclonal SFTPA1 + 2 | Abcam | Cat# AB206299 RRID:AB_2810211 | IHC, 1:250 WB, 1:1000 |
| Antibody                          | Goat polyclonal SFTPA | Santa Cruz | Cat# SC-699 RRID:AB_661292 | IHC, 1:100 WB, 1:1000 |
| Antibody                          | Goat polyclonal SFTPA | Santa Cruz | Cat# SC-7700 RRID:AB_661293 | IHC, 1:100 WB, 1:1000 |
| Antibody                          | Rabbit polyclonal SFTPA | Santa Cruz | Cat# SC-13977 RRID:AB_661294 | WB, 1:1000 |

Continued on next page
| Reagent type (species) or resource | Designation          | Source or reference | Identifiers          | Additional information                      |
|-----------------------------------|----------------------|---------------------|----------------------|---------------------------------------------|
| Antibody                         | Rabbit monoclonal Lysozyme | Abcam               | Cat# AB108508 RRID:AB_10861277 | IHC, 1:250, WB, 1:1000                     |
| Antibody                         | Goat polyclonal SFTPC  | Santa Cruz          | Cat# SC-7705 RRID:AB_2185505 | IHC, 1:250, WB, 1:1000                      |
| Antibody                         | Rabbit polyclonal SFTPC | Santa Cruz          | Cat# SC-13979 RRID:AB_2185502 | WB, 1:1000                                  |
| Antibody                         | Goat polyclonal CCA    | Santa Cruz          | Cat# SC-9772 RRID:AB_2238819 | IHC, 1:1000                                |
| Antibody                         | Goat polyclonal AQP5   | Santa Cruz          | Cat# SC-9890 RRID:AB_2059877 | IHC, 1:50                                   |
| Antibody                         | Rabbit polyclonal NR5A2 | Abcam               | Cat# AB153944 RRID:AB_2810212 | WB, 1:1000                                 |
| Recombinant DNA reagent          | M50 Super 8x TOPFlash | Addgene             | Plasmid #12456 RRID:Addgene_12456 | Vector used to build SFTP Luciferase reporters |
| Recombinant DNA reagent          | pCDNA3-mLRH1          | Holly Ingraham      | Ms NR5A2 expression vector |                                             |
| Recombinant DNA reagent          | pDTA-TK               | Addgene             | Plasmid #22677 RRID:Addgene_22677 | Empty targeting vector for mouse production |
| Recombinant DNA reagent          | MSCV-NKX2.1           | Addgene             | Plasmid #31271 RRID:Addgene_31271 | NKX2.1 expression vector                     |
| Recombinant DNA reagent          | PCDH-FOXA1            | Eric Snyder         | FOXA1 expression vector |                                             |
| Recombinant DNA reagent          | FUW-mKate             | This paper          | Fluorescent protein mKate expression vector used for assaying transfection efficiency | |
| Recombinant DNA reagent          | GFP-PGC1              | Addgene             | Plasmid #4 RRID:Addgene_4 | PGC1α expression vector                     |
| Recombinant DNA reagent          | pWZL-Hygro            | Addgene             | Plasmid #18750 RRID:Addgene_18750 | Empty vector used to normalize amount of DNA transfected |
| Recombinant DNA reagent          | SFTPA-LUC             | This paper          | 5 kb SFTPα promoter in luciferase reporter | |
| Recombinant DNA reagent          | SFTPB-LUC             | This paper          | 5 kb SFTPβ promoter in luciferase reporter | |
| Recombinant DNA reagent          | SFTPC-LUC             | This paper          | 5 kb SFTPγ promoter in luciferase reporter | |
| Peptide, recombinant protein     | TAT-CRE               | Excellgen           | Cat# Eg-1001          | Cell permeant CRE protein                    |
| Commercial assay or kit          | Dynabeads protein G IP kit | Thermo              | Cat# 10007D           |                                             |
| Commercial assay or kit          | Pierce firefly luc one step glow assay kit | Thermo              | Cat# 16196           |                                             |

Continued on next page
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|----------------------------------|-------------|--------------------|-------------|------------------------|
| Software, algorithm | MEME | http://meme-suite.org | Multiple Em Motif Elucidation |
| Software, algorithm | FIMO | http://meme-suite.org | Find Individual MOtifs |
| Software, algorithm | GSEA | http://gsea.org | Gene Set Enrichment Analysis |
| Software, algorithm | R | http://rstudio.com | R programming language |
| Software, algorithm | Custom R scripts | github.com/jevanveen/vanveen-elife | Referenced scripts hosted at GitHub |
| Other | Antigen Retrieval | Syrbu and Cohen, 2011 | Antigen Retrieval Method for Immunostaining of Paraffin Sections |
| | | | Method greatly aiding in immunostaining |

**Contact for reagent and resource sharing**

Further information and requests for reagents should be directed to and will be fulfilled by the Lead Contact, Martin McMahon (martin.mcmahon@hci.utah.edu).

**Biological vs technical replication**

Individual animals, tumors, and different cell lines comprise independent biological replicates. Repeated testing on the same cell line is considered technical replication.

**Experimental model: Mice**

All mouse work was done with the approval of either the University of California IACUC under approval #AN089594 or the University of Utah IACUC under approval #15-11014. Mice were housed in microisolator cages on ventilated racks in AAALAC accredited vivaria. Mice were housed in groups, as possible, and were provided bedding enrichment. Animals were provided standard laboratory rodent chow or Capecchi’s breeder diet when appropriate. Cages were supplied with water via a lixit system built into the housing rack or with a water bottle placed in the microisolator cage. Institute husbandry staff performed twice daily health checks. For breeding purposes, FVB/N and C57BL/6J mice were obtained from the Jackson Laboratory. In all animal experiments, animals were age matched to within 4 weeks of one another, all being between 3 to 4 months old. A power analysis was conducted in R to determine the number of animals to include based on RNA-Seq data of Sftpa from a previous experiment (power.t.test(delta = 2895.4, sd = 918, sig.level = 0.05, power = 0.8)) indicating 3.4 mice per group would be sufficient to see a 2-fold difference. This was rounded up and four mice were initiated for each time point and genotype. Equal numbers of male and female mice were selected for each time point and genotype. Mice were then randomized within sex and genotype and assigned to groups for harvest at different time points such that at each time point, 2 females and two males were euthanized for analysis. All mice used in these experiments were completely drug naïve and had never undergone other experimental procedures. Mice were on a mixed background of C57BL/6, 129, and FVB. Tumor initiation was performed by experimenters blinded to genotype.

**Experimental model: Cell lines**

MLE-12 immortalized lung cells were newly obtained from ATCC and therefore assumed to be of the correct identity and to be free of mycoplasma contamination. MLE-12 cells were cultured in HITES medium supplemented with 2% FBS (HyClone) and penicillin/streptomycin. 293 T cells were from a frozen lab stock, whose identity was confirmed by STR profiling at the Huntsman Cancer Institute DNA sequencing core, and whose mycoplasma contamination status was confirmed to be
negative by PCR. 293 T cells were maintained in DMEM (Life Technologies) supplemented with 10% FBS (HyClone) and supplemented with 5 mM glutamine and penicillin/streptomycin.

Vector construction

All PCR steps were performed with CloneAmp (Clontech) high-fidelity polymerase premix and all newly constructed vectors were verified by Sanger sequencing. The targeting vector used to produce the BrAfCAT mouse strain was built by the cloning of three fragments into the dual selection targeting vector pDTA-TK. Two fragments, comprising 4.8 kb and 3.8 kb targeting homology arms were amplified from a C57BL/6J BAC containing the mouse BrAf locus. A third fragment comprising the entirety of the genetically engineered module was assembled by gene synthesis (Genewiz). The three fragments were cloned into the AGEI site of pDTA-TK using In-Fusion (Clontech).

New luciferase reporter constructs for the promoters of mouse surfactant proteins A, B, and C were created by amplification of mouse genomic DNA from a tail biopsy. Primer blast (NCBI) was used to create primers which captured 4500–5500 base pairs of promoter sequence beginning with the bases found immediately before the first annotated transcribed exon (ensembl.org). The TCF/LEF sites found in the M50 Super Top Flash construct were removed by digestion with KpnI and XhoI and In-Fusion was used to clone the Sftpa, B, or C promoters in their place. The FUW-Kate plasmid was constructed by gene synthesis (IDT) of sequence encoding the mKate2 red fluorophore with ends compatible for In-Fusion cloning into the EcoRI and BamHI sites of FUW.

ES cell targeting and screening

The BrAfCAT targeting construct was linearized by restriction enzyme digestion with the rare cutting enzyme I-CeuI and electroporated into 2H1 BrAfCAT+ ES cells, which were selected for construct integration using puromycin. Three 96-well plates of resistant clones were screened via PCR using one primer specific to the targeting construct and one primer found in the mouse genome, outside of the construct homology arms, such that a 4.8 kb product would be the result of homologous targeting construct integration, whereas integration by NHEJ would yield no product. Cell permeant TAT-CRE was added directly to culture media at a final concentration of 1 uM to test for functionality and CRE dependence of the fluorophore. Purified TAT-CRE was obtained from Excellgen (Rockville, MD).

Tumor induction

Mice were euthanized for analysis of lung tumor cell fluorescence at 2, 6, or 12 weeks p.i. Mice destined for lung harvest at either 2 or 6 weeks were initiated with 10^7 pfu of Ad5-Sftpcre (Fasbender et al., 1998; Sutherland et al., 2014). Mice destined for lung harvest at 12 weeks were initiated with a lower titer (10^6 pfu) of Ad5-Sftpcre to avoid encountering premature endpoints due to tumor burden.

Tissue harvest

At euthanasia, mice were perfused by first cutting the vena cava caudalis underneath the liver and then injection of DEPC treated PBS into the right ventricle of the heart until lungs turned white (Arlt et al., 2012). The cranial, medial and caudal lobes of the right lung were first taken and placed into ice cold PBS and placed on ice. A new syringe and needle containing 10% neutral buffered formalin (NBF) was inserted into the larynx of mice and 10 ml was slowly infused to initiate fixation of the remaining lung lobes. The two remaining partially fixed lung lobes were placed into 25 ml of NBF and incubated for 24 hr before being processed into paraffin and sectioned.

Tissue dissociation and FACS

Tumor bearing lungs were minced using fine scissors in a 0.5 mg/ml solution of Liberase TM (Roche). Minced tissue was incubated in a 37°C degree water bath for 15 min before being dissociated by pipetting up and down with a 1 ml pipette tip. Red blood cell lysis was performed by the addition of BD PharmLyse to 1x concentration and samples were incubated for an additional 10 min. Samples were passed through a 100 um filter fitted on a 50 ml conical tube. Filters were rinsed with 9 ml of ice cold Hanks Balanced Salt Solution (HBSS) and flow through was pelleted by centrifugation. From this point on, cells were kept on ice until lysis. Pellets were resuspended in 10 ml ice cold HBSS and...
passed through a 70 um filter affixed to the same 50 ml conical tube. Finally, dissociated cells were resuspended in 1 ml HBSS and passed through 35 um cell strainer cap into 5 mL round bottom polystyrene tubes. FACS was performed on a Becton-Dickinson ARIA III fitted with 100 uM nozzle, using gates as shown in the figures. tdTomato positive cells were sorted into RLT lysis buffer, homogenized and stored at −80°C until RNA purification.

Library Construction and Sequencing cDNA libraries for RNA-Sequencing experiments were produced by the High Throughput Genomics Core at the Huntsman Cancer Center. RNA was purified using the Qiagen RNeasy micro system. RNA integrity was assayed using the Agilent TapeStation 2200 and High Sensitivity RNA ScreenTapes. RNA data was included in final analyses if RINe values were above 6. No other exclusion of samples was done. For all samples, libraries were prepared using the Nugen Ovation Ultralow Library System V2. Libraries were sequenced using an Illumina HiSeq 2000 device with 50 single end cycles and v4 chemistry.

**Bioinformatics**

For RNA sequencing analysis, RNA transcript abundance was estimated using Salmon with default parameters on the main instance of the Galaxy webserver (https://usegalaxy.org). Differentially expressed genes were then determined by use of DESeq2 using default parameters on the main instance of the Galaxy webserver (https://usegalaxy.org), resulting in the datasets Figure 2—source data 1, Figure 7—source data 1. Gene set enrichment analysis was next performed using the R-package ‘fgsea’ with default parameters using the scripts provided as Figure 2—source code 1, Figure 3—source code 1, Figure 7—source code 1. Gene correlation network analysis was performed in the R-package ‘WGCNA’ with the following parameters: To decrease noise, genes were filtered for minimal expression (R-norm >40), leaving 14207 genes to be clustered. These genes were clustered in a single block with a soft-thresholding power of ‘3’ as recommended in the WGCNA documentation based on the scale free topology fit index of our data. WGCNA R script provided as Figure 6—source code 1, data provided as Figure 6—source data 1. For motif discovery, the promoter regions from the top 100 most specific AT2 marker genes were defined as 5 kb upstream of the transcriptional start site, and downloaded from biomart (https://www.ensembl.org/biomart). This list of sequences was filtered by repeat masker to remove low complexity DNA (repeatmasker.org). The filtered list was analyzed for enriched novel motifs using MEME (http://meme-suite.org) with default settings less the following parameters: Find 25 motifs of width between 6 and 25 nucleotides. Novel motifs were matched to known transcription factor motifs from human and mouse (HOCOMOCO v11 full) using TomTom (http://meme-suite.org) with default settings. To determine if PI3'-lipid signaling strength affects Ppargc1a transcript levels in human tumors, lung adenocarcinoma data were downloaded from the NCI Genomic Data Commons Data Portal and segregated into those cases predicted to have strong or weak activation of PI3'-lipid signaling (Figure 6—figure supplement 1—source data 1). The groups were defined as such: ‘Strong activation’ due to mutation in at least one of the following genes: Pik3ca, Pten, Pik3r1, and Akt1, ‘Unknown PI3K activation status’ due to none of these mutations being detectable. FPKM values for Ppargc1a were then compared between these two groups. This resulted in n = 211 control samples and n = 19 mutant samples with predicted strong activation of PI3K signaling. All R scripts written for this study are available at GitHub (van Veen, 2019; copy archived at https://github.com/elifesciences-publications/vanveen-elife).

**Tissue processing and antibody staining**

Harvested tissues were processed and embedded in paraffin, and sectioned at 4 uM. After deparaffinization in Citra-Clear (Stat Lab, McKinney, TX), sections were re-hydrated in an ethanol series and antigens were unmasked using heated incubation in Tris-EDTA-SDS (Syrbu and Cohen, 2011). Sections were blocked for non-specific interaction in 10% Normal Donkey Serum in PBS and antibody staining was performed using the following primary antibody concentrations: PGC1α (AB3242) 1:50. NKX2-1 (AB76013) 1:250. Phospho-S327-NKX2-1 (13608) 1:250. FOXA1 (AB23738) 1:250. FOXA2 (SC-7705) 1:250. CCA (SC-9772) 1:1000. AQP5 (SC-9890) 1:50. Primary antibody incubation was performed overnight at four degrees. After washing, alexa-488 and alexa-594 conjugated donkey anti mouse and donkey
anti rabbit secondary antibodies were diluted 1:250, and incubated on sections for 2 hr at room temperature. Stained sections were counterstained in DAPI and mounted in fluoromount G.

Microscopy and quantitation of immunofluorescent images
For overview see Figure 3—figure supplement 1. Fluorescent imaging in Figure 6d was performed on a Zeiss Apotome. Fluorescent imaging in Figure 5 was performed on a Leica DM1000. All other fluorescent imaging was performed on a Nikon Ti-E inverted microscope employing a high sensitivity Andor Clara CCD camera. All images being compared in figures and in quantification were captured at exactly the same parameters for light and exposure. Acquisition settings were set such that pixel intensities were below saturation within regions of interest. When image intensity scales were adjusted for clarity, the intensity scales of images compared were set at exactly the same input and output levels. Intensity scales were never modified before quantitation. Images of tumor bearing lungs were imported into NIH ImageJ, where individual tumors were traced, and matched TIFF files were exported for each available fluorescent channel. A custom pipeline was built in CellProfiler to identify tumor cells based first upon identifying tumor nuclei using NKX2-1 immunoreactivity, when available, or DAPI staining when NKX2-1 immunostaining had not been performed. Tumor cells were defined based on propagation from identified nuclei, and tumor cytoplasm was defined as tumor cell minus tumor nucleus. For tumors analyzed in Kras based models, tumors were more diffuse and intermingled with surrounding parenchyma and so identifying tumor cells based on propagation from nuclei led to poor performance, and so tumor cells were defined as a three pixel ring around the tumor nucleus. Measurements were taken from pertinent TIFF files within individual nuclear, cellular, and cytoplasmic objects. Data were exported into comma separated value files and imported into R Studio using a custom script. For the purposes of graphing, individual tumor cell points were graphed using a custom script employing the R function ggplot(). For all measurements, median fluorescence within each cellular object was the primary data output. For the purposes of quantification, tumor cells were not treated as independent, but whole tumor averages were considered (mean of median fluorescence values), and each tumor was treated as independent. Fluorescence was not assumed to fit a normal distribution, and as such two factor comparisons were done using Wilcoxon Rank Sum test to generate p values using the R function wilcoxon.test(). For comparisons of more than two conditions, one way ANOVA was performed using aov() followed by Tukey’s honest significant difference using TukeyHSD(). Chi-Squared tests were performed in R with the function chisq.test(). When quadrants were drawn defining ‘negative’ and ‘positive’ staining: BRAF^{V600E} driven tumors were noted to have relatively uniform positive expression of markers studied, and so ‘negative’ was defined as any tumor cell with median fluorescence less than one standard deviation below the mean of median fluorescence in BRAF^{V600E} driven tumor cells. For all imaging and quantification, images were captured from 2 to 4 separate animals bearing tumors per group. Specific scripts and data for figures as follows: Figure 3: CellProfiler pipeline (Figure 3—source code 3) used with raw images to produce Figure 3—source data 1, 2 and 3. Figure 3—source data 1, 2 and 3 then used with Figure 3—source code 2 to perform statistics and produce graphs. Figure 4: CellProfiler pipeline (Figure 4—source code 2 and Figure 4—source code 3) used with raw images to produce Figure 4—source data 1 and Figure 4—source data 2. Figure 4—source data 1 and 2 then used with Figure 4—source code 1 to perform statistics and produce graphs. Figure 5: Cellprofiler pipeline (Figure 5—source code 2) used with raw images to produce Figure 5—source data 1. Figure 5—source data 1 then used with Figure 5—source code 1 to perform statistics and produce graphs. Figure 7: CellProfiler pipeline (Figure 3—source code 3) used with raw images to produce Figure 7—source data 1. Figure 7—source data 1 then used with Figure 7—source code 2 to perform statistics and produce graphs.

Luciferase assays
Using Fugene 6, HEK293 cells were co-transfected with luciferase reporter constructs, candidate transcriptional regulators, a fluorescent reporter construct to measure transfection efficiency (FUW-Kate), and empty vector (pUC19) to standardize total amount of DNA transfected across conditions to 100 ng/well of 96 well plate. Transfection efficiency was measured by fluorescence on an Incucyte ZOOM automated microscopy system (https://www.essenbioscience.com/). Luciferase production was measured with the Pierce Firefly Luc One-Step Glow Assay Kit, normalized to transfection

DOI: https://doi.org/10.7554/eLife.43668
efficiency, and represented as fold change over cells transfected with no candidate transcriptional regulators. All assays were performed in triplicate. Data provided as Figure 7—source data 3.

**Protein biochemistry**

For immunoblot analysis of protein expression in MLE-12 cells, cells were lysed on ice in RIPA buffer supplemented with Thermo Halt protease inhibitor complex. Lysates were separated by acrylamide electrophoresis on pre-cast Novex 4–12% gradient Bis-Tris gels and transferred onto PVDF membranes using an Invitrogen iblot two transfer device. After blocking of non-specific interactions using Li-Cor blocking reagent, membranes were incubated in PBS containing antibodies at the following concentrations: SFTPC: (sc-13979) 1:1000; SFTPA: (sc-13977), 1:1000; NKX2-1: (ab76013), 1:1000; FOXA1: (58613), 1:2500; PGC1α: (ab3242), 1:500; NR5A2 (ab153944), 1:1000. Protocol was repeated twice for a total of n = 3 with equivalent results.

For co-immunoprecipitation experiments, 10 ug of the following antibodies were bound to Dynabeads magnetic Protein G beads (Ms anti-PGC1α (1F3.9), Rb anti-NKX2-1 (AB76013), Normal Rabbit IgG (CST#2729), Mouse IgG1 (CST#5415)) for 15 min at room temperature. All following steps were performed at four degrees centigrade. MLE-12 cells were lysed by 15 passages through a 25 gauge needle in the following buffer: 20 mM Tris HCl pH 8, 137 mM NaCl, 0.1%(v/v) Nonidet-P40. Lysates were centrifuged for 5 min at 1000xg to remove insoluble fraction. Cleared lysates were divided and incubated with either target antibody or IgG bound magnetic beads for 30 min before proceeding with washing and elution steps following product protocol. Eluates were separated by acrylamide electrophoresis on pre-cast Novex 4–12% gradient Bis-Tris gels and transferred onto PVDF membranes using an Invitrogen iblot two transfer device. After blocking of non-specific interactions using Li-Cor blocking reagent, membranes were incubated in PBS containing antibodies at the following concentrations: NKX2-1: (ab76013), 1:1000; PGC1α: (ab3242), 1:500. Protocol was repeated twice for a total of n = 3 with equivalent results.

**Acknowledgements**

The authors would like to thank: Tim Mosbruger in the Bioinformatics Core at the Huntsman Cancer Institute (HCI); The Embryonic Stem Cell Core at the University of California, San Francisco (UCSF); The Gladstone Transgenic Gene-Targeting Core at UCSF; The Pathology cores at both UCSF and HCI; Brian Dalley and the the High Throughput Genomics Core at the Huntsman Cancer Center; and The FACS Facility at the Helen Diller Comprehensive Cancer Center at UCSF. We also thank Joseph Juan for assistance in tumor induction, Alex Jones and Eric Snyder for generously sharing the PCDH-FOXA1 construct pre-publication, Eric Snyder for helpful discussions and critical manuscript editing, Stephanie Correa for helpful discussions and equipment usage, and Holly Ingraham for generously sharing the pCDNA3-mLRH1 construct pre-publication. Dr. McMahon and colleagues gratefully acknowledge philanthropic support for this research from Five for the Fight.

**Additional information**

**Competing interests**

Martin McMahon: Reviewing editor, eLife. The other authors declare that no competing interests exist.

**Funding**

| Funder | Grant reference number | Author |
|--------|------------------------|--------|
| National Cancer Institute | NCI R01_CA131261 | Martin McMahon |
| SASS | Postdoctoral Fellowship | J Edward van Veen Martin McMahon |
| University of California, San Francisco | Program for Breakthrough Biomedical Research | J Edward van Veen Martin McMahon |
| National Cancer Institute | ST32CA108462-1 | J Edward van Veen Martin McMahon |
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

**Author contributions**
J Edward van Veen, Conceptualization, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing—original draft, Project administration, Writing—review and editing; Michael Scherzer, Conceptualization, Data curation, Supervision, Investigation, Methodology, Writing—review and editing; Julia Boshuizen, Mollee Chu, Allison Landman, Shon Green, Conceptualization, Investigation, Writing—review and editing; Annie Liu, Investigation, Writing—review and editing; Christy Trejo, Martin McMahon, Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Project administration, Writing—review and editing.

**Author ORCIDs**
J Edward van Veen https://orcid.org/0000-0003-1798-3210
Martin McMahon https://orcid.org/0000-0003-2812-1042

**Ethics**
Animal experimentation: All mouse work was done with the approval of the University of California IACUC under approval AN089594. Mice were housed in microisolator cages on ventilated racks in an AAALAC accredited facility.

**Decision letter and Author response**
Decision letter https://doi.org/10.7554/eLife.43668.049
Author response https://doi.org/10.7554/eLife.43668.050

**Additional files**

**Supplementary files**
- Transparent reporting form
  DOI: https://doi.org/10.7554/eLife.43668.043

**Data availability**
Sequencing data have been deposited in GEO under accession code GSE123126. All R scripts written for this study are available at GitHub (https://github.com/jevanveen/vanveen-elife; copy archived at https://github.com/elifesciences-publications/vanveen-elife).

The following dataset was generated:

| Author(s)            | Year | Dataset title                                                                 | Dataset URL                                                                 | Database and Identifier                  |
|----------------------|------|------------------------------------------------------------------------------|-----------------------------------------------------------------------------|------------------------------------------|
| van Veen JE, Scherzer M, Boshuizen J, Chu M, Liu A, Landman A, Green S, McMahon M | 2018 | Mutationally-activated PI3'-kinase-α promotes de-differentiation of lung tumors initiated by the BRAFV600E oncoprotein kinase | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE123126 | NCBI Gene Expression Omnibus, GSE123126 |

The following previously published dataset was used:

| Author(s)            | Year | Dataset title                                                                 | Dataset URL                                                                 | Database and Identifier                  |
|----------------------|------|------------------------------------------------------------------------------|-----------------------------------------------------------------------------|------------------------------------------|
| Joshua D Campbell, Anton Alexandrov, Jaegil Kim, Jeremiah Wala, Alice H Berger, Chandra | 2016 | Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. | http://www.cbioportal.org/study?id=nsclc_tcga_broad_2016#summary               | cbioPortal, nsclc_tcga_broad_2016        |
References

Arlt MJ, Born W, Fuchs B. 2012. Improved visualization of lung metastases at single cell resolution in mice by combined in-situ perfusion of lung tissue and X-Gal staining of lacZ-tagged tumor cells. Journal of Visualized Experiments:e4162. DOI: https://doi.org/10.3791/4162, PMID: 22929213

Bailey TL, Boden M, Buske FA, Frith M, Grant CE, Clementi L, Ren J, Li WW, Noble WS. 2009. MEME SUITE: tools for motif discovery and searching. Nucleic Acids Research 37:W202–W208. DOI: https://doi.org/10.1093/nar/gkp335, PMID: 19458158

Bailey TL, Elkan C. 1994. Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proceedings. International Conference on Intelligent Systems for Molecular Biology 2:28–36. PMID: 7584402

Bruno MD, Bohinski RJ, Huelsman KM, Whitsett JA, Korfhagen TR. 1995. Lung cell-specific expression of the murine surfactant protein A (SP-A) gene is mediated by interactions between the SP-A promoter and thyroid transcription factor-1. Journal of Biological Chemistry 270:6531–6536. DOI: https://doi.org/10.1074/jbc.270.12.6531, PMID: 7896788

Camolotto SA, Pattabiraman S, Mosbruger TL, Jones A, Belova VK, Orstad G, Streiff M, Salmond L, Stubben C, Kaestner KH, Snyder EL. 2018. FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer. eLife 7:e38579. DOI: https://doi.org/10.7554/eLife.38579, PMID: 30475207

Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, Imielinski M, Hu X, Ling S, Akbani R, Rosenberg M, Cibulskis C, Ramachandran A, Collisson EA, Kwiatkowski DJ, Lawrence MS, et al. 2016. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nature Genetics 48:607–616. DOI: https://doi.org/10.1038/ng.3564, PMID: 27158780

Cassel TN, Berg T, Suske G, Nord M. 2002. Synergistic transactivation of the differentiation-dependent lung gene Clara cell secretory protein (secretoglobin 1a1) by the basic region leucine zipper factor CCAAT/enhancer-binding protein alpha and the homeodomain factor Nkx2.1/thyroid transcription factor-1. Journal of Biological Chemistry 277:36970–36977. DOI: https://doi.org/10.1074/jbc.M201293200, PMID: 6308467

Cassell TN, Berg T, Suske G, Nord M. 2002. Synergistic transactivation of the differentiation-dependent lung gene Clara cell secretory protein (secretoglobin 1a1) by the basic region leucine zipper factor CCAAT/enhancer-binding protein alpha and the homeodomain factor Nkx2.1/thyroid transcription factor-1. Journal of Biological Chemistry 277:36970–36977. DOI: https://doi.org/10.1074/jbc.M201293200, PMID: 12161423

Castellano E, Sheridan C, Thin MZ, Nye E, Spencer-Dene B, Diefenbacher ME, Moore C, Kumar MS, Murillo MM, Grönroos E, Lassally F, Stamp G, Downward J. 2013. Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance. Cancer Cell 24:617–630. DOI: https://doi.org/10.1016/j.ccr.2013.09.012, PMID: 24229709

Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, Huang F, He Y, Sun J, Tabori U, Kennedy M, Lieber DS, Roels S, White J, Otto GA, Ross JS, et al. 2017. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Medicine 9:34. DOI: https://doi.org/10.1186/s13073-017-0424-2, PMID: 28420421

Arlt MJ, Born W, Fuchs B. 2012. Improved visualization of lung metastases at single cell resolution in mice by combined in-situ perfusion of lung tissue and X-Gal staining of lacZ-tagged tumor cells. Journal of Visualized Experiments:e4162. DOI: https://doi.org/10.3791/4162, PMID: 22929213

Bailey TL, Boden M, Buske FA, Frith M, Grant CE, Clementi L, Ren J, Li WW, Noble WS. 2009. MEME SUITE: tools for motif discovery and searching. Nucleic Acids Research 37:W202–W208. DOI: https://doi.org/10.1093/nar/gkp335, PMID: 19458158

Bailey TL, Elkan C. 1994. Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proceedings. International Conference on Intelligent Systems for Molecular Biology 2:28–36. PMID: 7584402

Bruno MD, Bohinski RJ, Huelsman KM, Whitsett JA, Korfhagen TR. 1995. Lung cell-specific expression of the murine surfactant protein A (SP-A) gene is mediated by interactions between the SP-A promoter and thyroid transcription factor-1. Journal of Biological Chemistry 270:6531–6536. DOI: https://doi.org/10.1074/jbc.270.12.6531, PMID: 7896788

Camolotto SA, Pattabiraman S, Mosbruger TL, Jones A, Belova VK, Orstad G, Streiff M, Salmond L, Stubben C, Kaestner KH, Snyder EL. 2018. FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer. eLife 7:e38579. DOI: https://doi.org/10.7554/eLife.38579, PMID: 30475207

Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, Imielinski M, Hu X, Ling S, Akbani R, Rosenberg M, Cibulskis C, Ramachandran A, Collisson EA, Kwiatkowski DJ, Lawrence MS, et al. 2016. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nature Genetics 48:607–616. DOI: https://doi.org/10.1038/ng.3564, PMID: 27158780

Cassel TN, Berg T, Suske G, Nord M. 2002. Synergistic transactivation of the differentiation-dependent lung gene Clara cell secretory protein (secretoglobin 1a1) by the basic region leucine zipper factor CCAAT/enhancer-binding protein alpha and the homeodomain factor Nkx2.1/thyroid transcription factor-1. Journal of Biological Chemistry 277:36970–36977. DOI: https://doi.org/10.1074/jbc.M201293200, PMID: 6308467

Cassell TN, Berg T, Suske G, Nord M. 2002. Synergistic transactivation of the differentiation-dependent lung gene Clara cell secretory protein (secretoglobin 1a1) by the basic region leucine zipper factor CCAAT/enhancer-binding protein alpha and the homeodomain factor Nkx2.1/thyroid transcription factor-1. Journal of Biological Chemistry 277:36970–36977. DOI: https://doi.org/10.1074/jbc.M201293200, PMID: 12161423

Castellano E, Sheridan C, Thin MZ, Nye E, Spencer-Dene B, Diefenbacher ME, Moore C, Kumar MS, Murillo MM, Grönroos E, Lassally F, Stamp G, Downward J. 2013. Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance. Cancer Cell 24:617–630. DOI: https://doi.org/10.1016/j.ccr.2013.09.012, PMID: 24229709

Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, Huang F, He Y, Sun J, Tabori U, Kennedy M, Lieber DS, Roels S, White J, Otto GA, Ross JS, et al. 2017. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Medicine 9:34. DOI: https://doi.org/10.1186/s13073-017-0424-2, PMID: 28420421
Charles RP, Lezza G, Amendola E, Dankort D, McMahon M. 2011. Mutationally activated BRAF(V600E) elicits papillary thyroid Cancer in the adult mouse. Cancer Research 71:3863–3871. DOI: https://doi.org/10.1158/0008-5472.CAN-10-4463, PMID: 21512141

Charles RP, Silva J, Lezza G, Phillips WA, McMahon M. 2014. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Molecular Cancer Research 12:979–986. DOI: https://doi.org/10.1158/1541-7786.MCR-14-0158-T, PMID: 24770869

Chen W-J, Ho C-C, Chang Y-L, Chen H-Y, Lin C-A, Ling T-Y, Yu S-L, Yuan S-S, Louisa Chen Y-J, Lin C-Y, Pan S-H, Elizabeth Chou H-Y, Chen Y-J, Chang G-C, Chu W-C, Lee Y-M, Lee J-Y, Lee P-J, Li K-C, Chen H-W, et al. 2014. Cancer-associated fibroblasts regulate the plasticity of lung Cancer stemness via paracrine signalling. Nature Communications 5:e3472. DOI: https://doi.org/10.1038/ncomms4472

Cicchini M, Buza EL, Sagal KM, Gudiel AA, Durham AC, Feldser DM. 2017. Context-Dependent effects of amplified MAPK signaling during lung adenocarcinoma initiation and progression. Cell Reports 18:1958–1969. DOI: https://doi.org/10.1016/j.celrep.2017.01.069, PMID: 28228261

Daitoku H, Yamagata K, Matsuzaki H, Hatta M, Fukamizu A. 2003. Regulation of PGC-1 promoter activity by protein kinase B and the forkhead transcription factor FKHR. Diabetes 52:642–649. DOI: https://doi.org/10.2337/diabetes.52.3.642, PMID: 12605603

Dane KY, Chan LA, Rice JJ, Daugherty PS. 2006. Isolation of cell specific peptide ligands using fluorescent bacterial display libraries. Journal of Immunological Methods 309:120–129. DOI: https://doi.org/10.1016/j.jim.2005.11.021

Dankort D, Tlenova E, Collado M, Serrano M, Jones K, McMahon M. 2007. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced tumors. Genes & Development 21:379–384. DOI: https://doi.org/10.1101/gad.1516407, PMID: 17299312

Dankort D, Curley DP, Cartlidge RA, Nelson B, Kanzeis AN, Damsky WE, You M-J, DePinho RA, McMahon M, Bosenberg M. 2009. Braf(V600E) cooperates with pten loss to induce metastatic melanoma. Nature Genetics 41:544–552. DOI: https://doi.org/10.1038/ng.356, PMID: 19282848

DeFelice M, Silberschmidt D, DiLauro R, Xu Y, Wert SE, Weaver TE, Bachurski CJ, Clark JC, Whitsett JA. 2003. TTF-1 phosphorylation is required for peripheral lung morphogenesis, perinatal survival, and tissue-specific gene expression. Journal of Biological Chemistry 278:35574–35583. DOI: https://doi.org/10.1074/jbc.M304885200, PMID: 12829717

Desai TJ, Brownfield DG, Krasnow MA. 2014. Alveolar progenitor and stem cells in lung development, renewal and Cancer. Nature 507:190–194. DOI: https://doi.org/10.1038/nature13930, PMID: 24499815

Di Palma T, Nitsch R, Mascia A, Nitsch L, Di Lauro R, Zannini M. 2003. The paired domain-containing factor Pax8 and the homeodomain-containing factor TTF-1 directly interact and synergistically activate biological functions. Journal of Biological Chemistry 278:3395–3402. DOI: https://doi.org/10.1074/jbc.M205977200, PMID: 12441357

Drilon A, Laetsch TW, Kummara S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebelke RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascalenas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, et al. 2018. Efficacy of larotrectinib in TRK Fusion-Positive cancers in adults and children. The New England Journal of Medicine 378:731–739. DOI: https://doi.org/10.1056/NEJMoa1714448, PMID: 29466156

Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhayay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, Garcia-Echeverria C, Weisleder R, Mahmood U, Cantley LC, et al. 2008. Effective use of PI3K and MEK inhibitors to treat mutant kras G12D and PIK3CA H1047R murine lung cancers. Nature Medicine 14:1351–1356. DOI: https://doi.org/10.1038/nm.1890, PMID: 19029981

Fasbender A, Lee JH, Walters RW, Moninger TO, Zabner J, Welsh MJ. 1998. Incorporation of adenosine in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo. Journal of Biological Chemistry 273:184–193. DOI: https://doi.org/10.1074/jbc.273.1.184, PMID: 96495752

Garrett S, Duchak KL, McDonough RV, Dankort D. 2017. p53 loss does not permit escape from braf(V600E)-induced senescence in a mouse model of lung Cancer. Oncogene 36:1141–1153. DOI: https://doi.org/10.1038/onc.2017.235

Green S, Trejo CL, McMahon M. 2015. PIK3CA(H1047R) Accelerates and enhances KRAS(G12D)-Driven lung tumorigenesis. Cancer Research 75:5378–5391. DOI: https://doi.org/10.1158/0008-5472.CAN-15-1249, PMID: 26571140

Gupta S, Stamatoyannopoulos JA, Bailey TL, Noble WS. 2007a. Quantifying similarity between motifs. Genome Biology 8:R24. DOI: https://doi.org/10.1186/gb-2007-8-2-r24, PMID: 17324271

Gupta S, Ramjaun AR, Haiko P, Wang Y, Warner PH, Nicke B, Nye E, Stamp G, Alitalo K, Downward J. 2007b. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129:957–968. DOI: https://doi.org/10.1016/j.cell.2007.03.051, PMID: 17540175

Hamvas A, Deterding RR, Wert SE, White FV, Dishop MK, Alfano DN, Hallbacker AC, Planer B, Stephan MJ, Wargo JA, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, McMahon M. 2011. Oncogenic BRAF regulates oxidative
metabolism via PGC1α and MITF. Cancer Cell 23:302–315. DOI: https://doi.org/10.1016/j.ccr.2013.02.003, PMID: 23477830

Heist RS, Engelman JA. 2012. SnapShot: non-small cell lung Cancer. Cancer Cell 21:448–448.e2. DOI: https://doi.org/10.1016/j.ccr.2012.03.007, PMID: 22439939

Huillard E, Hashizume R, Phillips JJ, Griveau A, Ihrie RA, Aoki Y, Nicolaides T, Perry A, Waldman T, McMahon M, Weiss WA, Petritsch C, James CD, Rowitch DH. 2012. Cooperative interactions of BRAFV600E kinase and CDKNA2a locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. PNAS 109:8710–8715. DOI: https://doi.org/10.1073/pnas.1117255109, PMID: 22586120

Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, et al. 2015. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. The New England Journal of Medicine 373:726–736. DOI: https://doi.org/10.1056/NEJMoa1502309, PMID: 26287849

Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes & Development 15:3243–3248. DOI: https://doi.org/10.1101/gad.943001, PMID: 11751630

Juan J, Muraguchi T, Iezza G, Sears RC, McMahon M. 2014. Diminished WNT-β-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors. Genes & Development 28:561–575. DOI: https://doi.org/10.1101/gad.233627.113, PMID: 24589553

Kemper MF, Strone C, Krause DN, Duckles SP, Procaccio V. 2014. Genomic and non-genomic regulation of PGC1 isoforms by estrogen to increase cerebral vascular biogenesis and reactive oxygen species protection. European Journal of Pharmacology 723:322–329. DOI: https://doi.org/10.1016/j.ejphar.2013.11.009, PMID: 24227351

Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT, Jacks T. 2005. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121:823–835. DOI: https://doi.org/10.1016/j.cell.2005.03.032, PMID: 15960971

Kinross KM, Montgomery KG, Kleinschmidt M, Waring P, Ivetac I, Tikoo A, Saad M, Hare L, Roh V, Mantamadiotis T, Sheppard KE, Ryland GL, Campbell IG, Gorringe KL, Christensen JG, Cullinane C, Hicks RJ, Pearson RB, Johnstone RW, McArthur GA, et al. 2012. An activating Pik3ca mutation coupled with pten loss is sufficient to initiate ovarian tumorigenesis in mice. Journal of Clinical Investigation 122:553–557. DOI: https://doi.org/10.1172/JCI59309

Kwee KA, Kim YH, Girard L, Kao J, Pacyna-Gengelbach M, Salari K, Lee J, Choi YL, Sato M, Wang P, Hernandez-Boussard T, Gazdar AF, Petersen I, Minna JD, Pollack JR. 2008. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 27:3635–3640. DOI: https://doi.org/10.1038/sj.onc.1211012, PMID: 18212743

Langfelder P, Horvath S. 2008. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9:559. DOI: https://doi.org/10.1186/1471-2105-9-559

Lazzaro D, Price M, de Felice M, Di Lauro R. 1991. The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the foetal brain. Development 113:1093–1104. PMID: 1811929

Livet J, Weissman TA, Kang H, Draft RW, Lu J, Bennis RA, Sanes JR, Lichtman JW. 2007. Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous system. Nature 450:56–62. DOI: https://doi.org/10.1038/nature06293, PMID: 17972876

Madisen L, Zwingman TA, Sunkin SM, Oh SW, Zariwala HA, Gu H, Ng LL, Palmer RD, Hawrylycz MJ, Jones AR, Lein ES, Zeng H. 2010. A robust and high-throughput cre reporting and characterizing system for the whole mouse brain. Nature Neuroscience 13:133–140. DOI: https://doi.org/10.1038/nn.2467, PMID: 20023653

Maeda Y, Tsuchiya T, Hao H, Tompkins DH, Xu Y, Mucenski ML, Du L, Keiser AR, Fukazawa T, Naomoto Y, Nagayasu T, Whitsett JA. 2012. Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung. Journal of Clinical Investigation 122:4388–4400. DOI: https://doi.org/10.1172/JCI64048, PMID: 23143308

Mino P, Hamdan H, Bu D, Warburton D, Stepanik P, deLemos R. 1995. TTF-1 regulates lung epithelial morphogenesis. Developmental Biology 172:694–698. DOI: https://doi.org/10.1006/dbio.1995.8080, PMID: 8612983

Molina-Arcas M, Hancock DC, Sheridan C, Kumar MS, Downward J. 2013. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discovery 3:548–563. DOI: https://doi.org/10.1158/2159-8290.CD-12-0446, PMID: 23454899

Murillo MM, Rana S, Spencer-Dene B, Nye E, Stamp G, Downward J. 2018. Disruption of the interaction of RAS with PI3-Kinase induces regression of EGFR-Mutant Driven lung Cancer. Cell Reports 25:3545–3553. DOI: https://doi.org/10.1016/j.celrep.2018.12.003, PMID: 30590030

Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. 2007. A global double-fluorescent cre reporter mouse. Genesis 45:593–605. DOI: https://doi.org/10.1002/dvg.20335, PMID: 17868096

Pacheco-Pinedo EC, Durham AC, Stewart KM, Goss AM, Lu MM, Demayo FJ, Morrissey EE. 2011. Wnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. Journal of Clinical Investigation 121:1935–1945. DOI: https://doi.org/10.1172/JCI44871, PMID: 21490395

Park KS, Whitsett JA, Di Palma T, Hong JH, Yaffe MB, Zannini M. 2004. TAZ interacts with TTF-1 and regulates expression of surfactant protein-C. Journal of Biological Chemistry 279:17384–17390. DOI: https://doi.org/10.1074/jbc.M312569200, PMID: 14970209
Revel JP. 1960. Identification of glycogen in electron micrographs of thin tissue sections. The Journal of Cell Biology 8:575–589. DOI: https://doi.org/10.1083/jcb.8.3.575

Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J. 1994. Phosphatidylinositol-3-OH kinase as a direct target of ras. Nature 370:527–532. DOI: https://doi.org/10.1038/370527a0, PMID: 8052307

Rossell R, Carcereny E, Gervais R, Vergnenegre A, Masucci B, Felip E, Palermo R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Boyer I, Illanio A, et al. 2016. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung Cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The Lancet Oncology 13:239–246. DOI: https://doi.org/10.1016/S1470-2045(11)70393-X, PMID: 22285168

Sakamoto N, Feng Y, Stolfi C, Kurosu Y, Green M, Lin J, Green ME, Sentani K, Yasui W, McMahon M, Hardiman KM, Spence JR, Horita N, Greenson JK, Kuick R, Cho KR, Fearon ER. 2017. BRAFV600E cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis. eLife 6:e20331. DOI: https://doi.org/10.7554/eLife.20331, PMID: 28072391

Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abraão Miziara JE, Balint B, De Marinis F, Keller A, Aréu O, Csslak M, Albert I, Barrios CH, Grossi F, Krazowski M, Cupit L, Cihon F, Dimatteo S, Hanna N. 2010. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung Cancer. Journal of Clinical Oncology 28:1835–1842. DOI: https://doi.org/10.1200/JCO.2009.23.1321, PMID: 20212250

Schell JC, Wisidagama DR, Bensard C, Zhao H, Wei P, Tanner J, Flores A, Mohlan J, Sorensen UK, Earl CS, Olson KA, Miao R, Waller TC, Delker D, Kanth P, Jiang L, DeBerardinis RJ, Bronner MP, Li DY, Cox JE, et al. 2017. Control of intestinal stem cell function and proliferation by mitochondrial pyruvate metabolism. Nature Cell Biology 19:1027–1036. DOI: https://doi.org/10.1038/ncb3593, PMID: 28812582

Shai A, Dankort D, Juan J, Green S, McMahon M. 2015. TP53 silencing bypasses growth arrest of BRAFV600E-Induced lung tumor cells in a Two-Switch model of lung tumorigenesis. Cancer Research 75:3167–3180. DOI: https://doi.org/10.1158/0008-5472.CAN-14-3701, PMID: 26001956

Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O’Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, et al. 2014. Crizotinib versus chemotherapy in advanced ALK-positive lung Cancer. The New England Journal of Medicine 368:2385–2394. DOI: https://doi.org/10.1056/NEJMoa1401286, PMID: 23724913

Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, et al. 2014. Crizotinib in ROS1-rearranged non-small-cell lung Cancer. The New England Journal of Medicine 371:1963–1971. DOI: https://doi.org/10.1056/NEJMoa1406766, PMID: 25264305

Siegel RL, Miller KD, Jemal A. 2016. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians 66:7–30.

Snippert HJ, van der Flier LG, Sato T, van Es JH, van den Born M, Kroon-Veenboer C, Barker N, Klein AM, van Rheenen J, Simons BD, Clevers H. 2010. Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell 143:134–144. DOI: https://doi.org/10.1016/j.cell.2010.09.016, PMID: 20887898

Snyder EL, Watanabe H, Magendantz M, Hoersch S, Chen TA, Wang DG, Crowley D, Whitaker CA, Meyerson M, Kimura S, Jacks T. 2013. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Molecular Cell 50:185–199. DOI: https://doi.org/10.1016/j.molcel.2013.02.018, PMID: 23523371

Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, Jessell TM, Costantini F. 2001. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Developmental Biology 1:1027–1036. DOI: https://doi.org/10.1186/1471-213X-1-4, PMID: 11290402

Stahlman MT, Gray ME, Whitsett JA. 1996. Expression of thyroid transcription factor-1(TTF-1) in fetal and neonatal human lung. Journal of Histochemistry & Cytochemistry 44:673–678. DOI: https://doi.org/10.1177/44.7.867598, PMID: 867598

Sutherland KD, Song JY, Kwon MC, Proost N, Zevenhoven J, Berns A. 2014. Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma. PNAS 111:4952–4957. DOI: https://doi.org/10.1073/pnas.1319963111, PMID: 24586047

Sybran S, Cohen MB. 2011. An enhanced antigen-retrieval protocol for immunohistochemical staining of formalin-fixed, paraffin-embedded tissues. Methods in Molecular Biology 717:101–110. DOI: https://doi.org/10.1007/978-1-61779-024-9_6, PMID: 21370027

Trejo CL, Juan J, Vicent S, Sweet-Cordero A, McMahon M. 2012. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. Cancer Research 72:3048–3059. DOI: https://doi.org/10.1158/0008-5472.CAN-11-3649, PMID: 22151180

Trejo CL, Green S, Marsh V, Colisson EA, Iezza G, Phillips WA, McMahon M. 2013. Mutationally activated PIK3CA(H1047R) cooperates with BRAFV600E to promote lung Cancer progression. Cancer Research 73:6448–6451. DOI: https://doi.org/10.1158/0008-5472.CAN-13-0681, PMID: 24019382

Treutlein B, Brownfield DG, Wu AR, Neff NF, Mantalas GL, Espinoza FH, Desai TJ, Krasnow MA, Quake SR. 2014. Reconstructing lineage hierarchies of the distal lung epithelium using single-cell RNA-seq. Nature 509:371–375. DOI: https://doi.org/10.1038/nature13173, PMID: 24737565

Tsao H, Goel V, Wu H, Yang G, Haluska FG. 2004. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. Journal of Investigative Dermatology 122:337–341. DOI: https://doi.org/10.1046/j.0022-202X.2004.22243.x, PMID: 15009714
van Veen JE, Pringle DR, McMahon M. 2016. P2A-Fluorophore tagging of BRAF tightly links expression to fluorescence in vivo. PLOS ONE 11:e0157661. DOI: https://doi.org/10.1371/journal.pone.0157661, PMID: 27348307

van Veen JE. 2019. vanveen-elife. GitHub. 64fb003. https://github.com/jevanveen/vanveen-elife

Vivanco I, Sawyers CL. 2002. The phosphatidylinositol 3-Kinase AKT pathway in human Cancer. Nature Reviews Cancer 2:489–501. DOI: https://doi.org/10.1038/nrc839, PMID: 12094235

Wang J, Kobayashi T, Floch N, Kinkade CW, Aytes A, Dankort D, Lefebvre C, Mitrofanova A, Cardiff RD, McMahon M, Califano A, Shen MM, Abate-Shen C. 2012. B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate Cancer. Cancer Research 72:4765–4776. DOI: https://doi.org/10.1158/0008-5472.CAN-12-0820, PMID: 22836754

Wikenheiser KA, Vorbroker DK, Rice WR, Clark JC, Bachurski CJ, Oie HK, Whitsett JA. 1993. Production of immortalized distal respiratory epithelial cell lines from surfactant protein C/simian virus 40 large tumor antigen transgenic mice. PNAS 90:11029–11033. DOI: https://doi.org/10.1073/pnas.90.23.11029, PMID: 8248207

Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, Hubbard DD, DuPage MJ, Whittaker CA, Hoersch S, Yoon S, Crowley D, Bronson RT, Chiang DY, Meyerson M, Jacks T. 2011. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473:101–104. DOI: https://doi.org/10.1038/nature09881, PMID: 21471965

Yatabe Y, Mitsudomi T, Takahashi T. 2002. TTF-1 expression in pulmonary adenocarcinomas. The American Journal of Surgical Pathology 26:767–773. DOI: https://doi.org/10.1097/00000478-200206000-00010, PMID: 12023581

Yazawa T, Inaoka Y, Okada R, Mizutani T, Yamazaki Y, Usami Y, Kuribayashi M, Orisaka M, Umezawa A, Miyamoto K. 2010. PPAR-gamma coactivator-1alpha regulates progesterone production in ovarian granulosa cells with SF-1 and LRH-1. Molecular Endocrinology 24:485–496. DOI: https://doi.org/10.1210/me.2009-0352, PMID: 20133449

Yi M, Tong GX, Murry B, Mendelson CR. 2002. Role of CBP/p300 and SRC-1 in transcriptional regulation of the pulmonary surfactant protein-A (SP-A) gene by thyroid transcription factor-1 (TTF-1). Journal of Biological Chemistry 277:2997–3005. DOI: https://doi.org/10.1074/jbc.M109793200, PMID: 11713256

Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, Park BJ, Rusch VW, Travis WD. 2011. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Modern Pathology 24:653–664. DOI: https://doi.org/10.1038/modpathol.2010.232, PMID: 21252858

Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, Elder DE, Van Belle P, Gimotty P, Guerra M, Hammond R, Nathanson KL, Dalla Palma M, Herlyn M, Xu X. 2009. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. The American Journal of Pathology 174:2367–2377. DOI: https://doi.org/10.1016/j.ajpath.2009.081057, PMID: 19389934

Yuan B, Li C, Kimura S, Engelhardt RT, Smith BR, Minoo P. 2000. Inhibition of distal lung morphogenesis in Nkx2.1(-/-) embryos. Developmental Dynamics 217:180–190. DOI: https://doi.org/10.1002/(SICI)1097-0177(200002)217:2<180::AID-DVDY5>3.0.CO;2-3, PMID: 10706142

Yuan TL, Cantley LC. 2008. PI3K pathway alterations in Cancer: variations on a theme. Oncogene 27:5497–5510. DOI: https://doi.org/10.1038/onc.2008.245, PMID: 18794884